| 1 |
Elbehiry A, Marzouk E, Aldubaib M, Abalkhail A, Anagreyyah S, Anajirih N, Almuzaini AM, Rawway M, Alfadhel A, Draz A, Abu-okail A. Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. Antibiotics 2023;12:191. [DOI: 10.3390/antibiotics12020191] [Reference Citation Analysis]
|
| 2 |
Zhang L, Huang H, Wang Z, Fang X, Hong H, Chen Y, Ren Q, Yao Y, Chen Z, Pan F, Li X, Chen M, Lin T. A study on the prevention of hemorrhage and perforation in patients with primary gastric diffuse large-B cell lymphoma during treatment with immunochemotherapy. Cancer Med 2023. [PMID: 36621835 DOI: 10.1002/cam4.5486] [Reference Citation Analysis]
|
| 3 |
Braendli T, Schindler V, Braun DL, Murray FR, Hente JM, Pohl D. Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland. Swiss Med Wkly 2023;153:40024. [PMID: 36652712 DOI: 10.57187/smw.2023.40024] [Reference Citation Analysis]
|
| 4 |
Yunusa I, Love BL. Cost-Effectiveness of Vonoprazan- and Rifabutin-Based vs. Other Regimens as First-Line Treatment of Helicobacter Pylori Infection in the United States. Am J Gastroenterol 2022. [PMID: 36693030 DOI: 10.14309/ajg.0000000000002146] [Reference Citation Analysis]
|
| 5 |
Mansour-ghanaei F, Masihipour B, Fathalipour M, Hassanipour S, Sokhanvar H, Mansour-ghanaei A, Asgharnezhad M, Joukar F. The Efficacy, Safety, and Tolerability of Levofloxacin Quadruple Therapy for Helicobacter pylori Eradication: A Randomized, Double-Blind Clinical Trial. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-7. [DOI: 10.1155/2022/9794901] [Reference Citation Analysis]
|
| 6 |
Fahim M, Sohail M, Sajjad Khan M, Khan FU, Ur Rashid S, Akhter S. Frequency of Bleeding Duodenal Ulcer in Patients Presenting with Upper Gastrointestinal Bleeding. PJHS 2022. [DOI: 10.54393/pjhs.v3i06.308] [Reference Citation Analysis]
|
| 7 |
Liang B, Yuan Y, Peng XJ, Liu XL, Hu XK, Xing DM. Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Front Cell Infect Microbiol 2022;12:1042070. [PMID: 36506013 DOI: 10.3389/fcimb.2022.1042070] [Reference Citation Analysis]
|
| 8 |
Lee BS, So HM, Kim S, Kim JK, Kim J, Kang D, Ahn M, Ko Y, Kim KH. Comparative evaluation of bioactive phytochemicals in Spinacia oleracea cultivated under greenhouse and open field conditions. Arch Pharm Res 2022. [DOI: 10.1007/s12272-022-01416-z] [Reference Citation Analysis]
|
| 9 |
Jambi LK. Systematic Review and Meta-Analysis on the Sensitivity and Specificity of 13C/14C-Urea Breath Tests in the Diagnosis of Helicobacter pylori Infection. Diagnostics (Basel) 2022;12:2428. [PMID: 36292117 DOI: 10.3390/diagnostics12102428] [Reference Citation Analysis]
|
| 10 |
Huard K, Haddad K, Saada Y, Nguyen J, Banon D, Matteau A, Mansour S, Potter BJ. Prevalence of H. pylori among patients undergoing coronary angiography (The HP-DAPT prevalence study). Sci Rep 2022;12:16591. [PMID: 36198683 DOI: 10.1038/s41598-022-17034-0] [Reference Citation Analysis]
|
| 11 |
Correia C, Almeida N, Leal C, Branquinho D, Fernandes A, Gravito-Soares E, Calhau C, Bastos I, Vasconcelos H, Figueiredo P. Single-capsule bismuth-based quadruple therapy as a rescue therapy for Helicobacter pylori eradication. Scand J Gastroenterol 2022;:1-5. [PMID: 36189844 DOI: 10.1080/00365521.2022.2119097] [Reference Citation Analysis]
|
| 12 |
Jung YS, Kim S, Kim HY, Noh SJ, Park JH, Park CH. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence. J Gastroenterol Hepatol 2022;37:1911-8. [PMID: 35816283 DOI: 10.1111/jgh.15939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Demir B, Küçük NÖ, Baltacıoğlu MH. Nostalgic Nuclear Medicine Applications in Gastrointestinal System Disorders. nts 2022;8:120-126. [DOI: 10.4274/nts.galenos.2022.0013] [Reference Citation Analysis]
|
| 14 |
Jeong SY, Na MW, Park EC, Kim J, Kang D, Hamishehkar H, Ahn M, Kim JK, Kim KH. Labdane-type Diterpenes from Pinus eldarica Needles and Their Anti- Helicobacter pylori Activity. ACS Omega. [DOI: 10.1021/acsomega.2c04147] [Reference Citation Analysis]
|
| 15 |
Kim SE, Hwang JH. Management of Helicobacter pylori Infection: A Comparison between Korea and the United States. Gut Liver 2022;16:503-14. [PMID: 35843686 DOI: 10.5009/gnl210224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Na MW, Jeong SY, Ko Y, Kang D, Pang C, Ahn M, Kim KH. Chemical Investigation of Tetradium ruticarpum Fruits and Their Antibacterial Activity against Helicobacter pylori. ACS Omega. [DOI: 10.1021/acsomega.2c02380] [Reference Citation Analysis]
|
| 17 |
Çardak Hakbilen M, Halhalli HC, Köksal Şimşek T, Özerol H, Tinmaz İ, Karakayali O. Effectiveness of Clinical Scoring Systems in Duration of Hospital Stay, Transfusion Need and Prediction of Re-Bleeding in Patients Admitted to the Emergency Department for Upper Gastrointestinal System Bleeding. Sakarya Medical Journal 2022. [DOI: 10.31832/smj.1037148] [Reference Citation Analysis]
|
| 18 |
Dawod HM. A prospective study for evaluating the effect of gastric targeted biopsy sampling with I‐scan optical enhancement on the diagnostic yield of CLOtest for Helicobacter pylori infection. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.621] [Reference Citation Analysis]
|
| 19 |
Ansari S, Yamaoka Y. Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance. Clin Microbiol Rev 2022;:e0025821. [PMID: 35404105 DOI: 10.1128/cmr.00258-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Vanden Bulcke A, Waked B, Haems L, Lambrecht G, Hervent AS, Alliet G, Baert F, Vervaeke S. Antimicrobial resistance of Helicobacter pylori in West Flanders - Belgium: an observational cross-sectional study. Acta Clin Belg 2022;77:360-7. [PMID: 33502281 DOI: 10.1080/17843286.2021.1872307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Na MW, Lee E, Kang D, Jeong SY, Ryoo R, Kim C, Ahn M, Kang KB, Kim KH. Identification of Antibacterial Sterols from Korean Wild Mushroom Daedaleopsis confragosa via Bioactivity- and LC-MS/MS Profile-Guided Fractionation. Molecules 2022;27:1865. [DOI: 10.3390/molecules27061865] [Reference Citation Analysis]
|
| 22 |
Mori D, John JL, Sabri SIB, Shaharom SMB, Iha H, Yamaoka Y, Matsumoto T, Ahmed K. Seroepidemiological survey of the prevalence of Helicobacter pylori infection in Sabah, Malaysia. IJID Regions 2022;2:126-129. [DOI: 10.1016/j.ijregi.2021.12.012] [Reference Citation Analysis]
|
| 23 |
Han L, Shu X, Wang J. Helicobacter pylori-Mediated Oxidative Stress and Gastric Diseases: A Review. Front Microbiol 2022;13:811258. [PMID: 35211104 DOI: 10.3389/fmicb.2022.811258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 24 |
Lee S, Alishir A, Kim TW, Kang D, Ryoo R, Pang C, Ahn M, Kim KH. First Chemical Investigation of Korean Wild Mushroom, Amanita hemibapha subsp. javanica and the Identification of Anti-Helicobacter pylori Compounds. Pharmaceuticals 2022;15:152. [DOI: 10.3390/ph15020152] [Reference Citation Analysis]
|
| 25 |
Lee S, Kim TW, Lee YH, Kang D, Ryoo R, Ko Y, Ahn M, Kim KH. Two New Fatty Acid Derivatives, Omphalotols A and B and Anti-Helicobacterpylori Fatty Acid Derivatives from Poisonous Mushroom Omphalotus japonicus. Pharmaceuticals 2022;15:139. [DOI: 10.3390/ph15020139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 26 |
Levitan BN, Skvortsov VV, Samokhvalova PD. Modern approaches in treatment of helicobacteriosis in patients with peptic ulcer. Medicinskij alfavit 2022. [DOI: 10.33667/2078-5631-2021-40-7-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 27 |
Maioli ME, Frange RFN, Grion CMC, Delfino VDA. Helicobacter pylori eradication in renal transplant candidates. J Bras Nefrol 2022:S0101-28002022005001401. [PMID: 35014666 DOI: 10.1590/2175-8239-JBN-2021-0097] [Reference Citation Analysis]
|
| 28 |
Ibrahim N, El Said H, Choukair A. Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study. World J Clin Cases 2022; 10(1): 227-235 [DOI: 10.12998/wjcc.v10.i1.227] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 29 |
Kim Y, Chung WC. Bismuth-containing Standard Triple Therapy the First-line Eradication Therapy for Helicobacter pylori. Korean J Helicobacter Up Gastrointest Res 2021;21:354-8. [DOI: 10.7704/kjhugr.2021.0027] [Reference Citation Analysis]
|
| 30 |
Zihlif M, Bashaireh B, Rashid M, Almadani Z, Jarrar Y. Effect of major CYP2C19 genetic polymorphisms on Helicobacter pylori eradication based on different treatment regimens. Biomed Rep 2022;16:2. [PMID: 34820125 DOI: 10.3892/br.2021.1485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 31 |
Wylie MR, Windham IH, Blum FC, Wu H, Merrell DS. In vitro antibacterial activity of nimbolide against Helicobacter pylori. J Ethnopharmacol 2021;:114828. [PMID: 34763046 DOI: 10.1016/j.jep.2021.114828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 32 |
Boonyabaramee P, Pittayanon R, Sunpavat A, Lerttanatum N, Faknak N, Wisedopas N. The Helicobacter pylori detection rate by using combination of rapid urease test at antrum and body vs histopathology in population who stop proton pump inhibitor less than 2 weeks. GastroHep 2021;3:339-343. [DOI: 10.1002/ygh2.496] [Reference Citation Analysis]
|
| 33 |
Aung WP, Aye TT, Aye KS, Kyaw AMM. Levofloxacin‐based Helicobacter pylori eradication in chronic dyspepsia. GastroHep 2021;3:394-400. [DOI: 10.1002/ygh2.478] [Reference Citation Analysis]
|
| 34 |
Grande R, Carradori S, Puca V, Vitale I, Angeli A, Nocentini A, Bonardi A, Gratteri P, Lanuti P, Bologna G, Simeone P, Capasso C, De Luca V, Supuran CT. Selective Inhibition of Helicobacter pylori Carbonic Anhydrases by Carvacrol and Thymol Could Impair Biofilm Production and the Release of Outer Membrane Vesicles. Int J Mol Sci 2021;22:11583. [PMID: 34769015 DOI: 10.3390/ijms222111583] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 35 |
Yuan C, Lin XM, Ou Y, Cai L, Cheng Q, Zhou P, Liao J. Association between regular arrangement of collecting venules and Helicobacter pylori status in routine endoscopy. BMC Gastroenterol 2021;21:389. [PMID: 34670510 DOI: 10.1186/s12876-021-01960-w] [Reference Citation Analysis]
|
| 36 |
Noronha BP, Mambrini JVM, Torres KCL, Martins-Filho OA, Teixeira-Carvalho A, Lima-Costa MF, Peixoto SV. Chlamydia pneumoniae and Helicobacter pylori infections and immunological profile of community-dwelling older adults. Exp Gerontol 2021;156:111589. [PMID: 34637947 DOI: 10.1016/j.exger.2021.111589] [Reference Citation Analysis]
|
| 37 |
Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 2021;26:6078. [PMID: 34641620 DOI: 10.3390/molecules26196078] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 38 |
Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, Akyıldız E, Topbaş M, Özgür O, Arslan M. Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol 2020;31:221-33. [PMID: 32343234 DOI: 10.5152/tjg.2020.18631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 39 |
Durazzo M, Adriani A, Fagoonee S, Saracco GM, Pellicano R. Helicobacter pylori and Respiratory Diseases: 2021 Update. Microorganisms 2021;9:2033. [PMID: 34683354 DOI: 10.3390/microorganisms9102033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 40 |
Baek SM, Kim N, Kwon YJ, Lee HS, Kim HY, Lee J, Yoon H, Shin CM, Park YS, Lee DH. Role of Serum Pepsinogen II and Helicobacter pylori Status in the Detection of Diffuse-Type Early Gastric Cancer in Young Individuals in South Korea. Gut Liver 2020;14:439-49. [PMID: 31533397 DOI: 10.5009/gnl19091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 41 |
Lestari HM, Gustinanda J, Tejaputri NA, Tumpu NA, Radifan T, Louisa M. Stool Antigen Examination as a Diagnostic Tool for Dyspeptic Patient caused by Helicobacter pylori Infection: A Case-based Literature Review. Open Access Maced J Med Sci 2021;9:305-309. [DOI: 10.3889/oamjms.2021.5568] [Reference Citation Analysis]
|
| 42 |
Frater JL. Trends in iron deficiency anemia research 2001-2020: A bibliometric analysis. World J Meta-Anal 2021; 9(4): 389-404 [DOI: 10.13105/wjma.v9.i4.389] [Reference Citation Analysis]
|
| 43 |
Du L, Liu J, Jin C, Ma Y, Yin L, Man S, Li S, Li L, Ning Y, Zhang X. Association between Helicobacter pylori infection and carotid atherosclerosis in Chinese adults. Atheroscler Plus 2021;44:25-30. [PMID: 36644666 DOI: 10.1016/j.athplu.2021.08.004] [Reference Citation Analysis]
|
| 44 |
Cheha KM, Dib SOA, Alhalabi MM. Pilot study: Comparing efficacy of 14-day triple therapy Clarithromycin versus levofloxacin on eradication of Helicobacter pylori infection in Syrian population single-center experience. Avicenna J Med 2018;8:14-7. [PMID: 29404268 DOI: 10.4103/ajm.AJM_70_17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 45 |
Singh SP, Ahuja V, Ghoshal UC, Makharia G, Dutta U, Zargar SA, Venkataraman J, Dutta AK, Mukhopadhyay AK, Singh A, Thapa BR, Vaiphei K, Sathiyasekaran M, Sahu MK, Rout N, Abraham P, Dalai PC, Rathi P, Sinha SK, Bhatia S, Patra S, Ghoshal U, Poddar U, Mouli VP, Kate V. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian J Gastroenterol 2021;40:420-44. [PMID: 34219211 DOI: 10.1007/s12664-021-01186-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 46 |
Obaid Saleh R, Shihab Ahmed N, Ewais EA, Shakir Mahmood A, Sofy AR. Frequency of virulence factor of Helicobacter pylori and IL17 gene expression related with gastric ulcer patient. Materials Today: Proceedings 2021. [DOI: 10.1016/j.matpr.2021.06.345] [Reference Citation Analysis]
|
| 47 |
Sayer JR, Walldén K, Koss H, Allan H, Daviter T, Gane PJ, Waksman G, Tabor AB. Design, synthesis, and evaluation of peptide-imidazo[1,2-a]pyrazine bioconjugates as potential bivalent inhibitors of the VirB11 ATPase HP0525. J Pept Sci 2021;:e3353. [PMID: 34142414 DOI: 10.1002/psc.3353] [Reference Citation Analysis]
|
| 48 |
Keller J, Hammer HF, Afolabi PR, Benninga M, Borrelli O, Dominguez-Munoz E, Dumitrascu D, Goetze O, Haas SL, Hauser B, Pohl D, Salvatore S, Sonyi M, Thapar N, Verbeke K, Fox MR; European 13C-breath test group. European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC. United European Gastroenterol J 2021;9:598-625. [PMID: 34128346 DOI: 10.1002/ueg2.12099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 49 |
Frater JL. The Top 100 Cited Papers in the Field of Iron Deficiency in Humans: A Bibliometric Study. Biomed Res Int 2021;2021:5573790. [PMID: 34235219 DOI: 10.1155/2021/5573790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Pozdeeva AO, Pozdeev OK, Gulyaev PE, Valeeva YV, Savinova AN. Current development of <i>Helicobacter pylori</i> eradication protocols. Russian Journal of Infection and Immunity 2021;11:1037-1049. [DOI: 10.15789/2220-7619-cdo-1679] [Reference Citation Analysis]
|
| 51 |
Kim YJ, Chung WC, Kim DB. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection. Helicobacter 2021;26:e12792. [PMID: 33650225 DOI: 10.1111/hel.12792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 52 |
Van den Poel B, Gils S, Micalessi I, Carton S, Christiaens P, Cuyle PJ, Moons V, Van Olmen G, Smismans A, Bourgain C, Bossuyt P, Frans J. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay. Acta Clin Belg 2021;76:177-83. [PMID: 31662122 DOI: 10.1080/17843286.2019.1685741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 53 |
Kavya G, Sharma BS, Rani PS. “PREVALENCE OF H.PYLORI INFECTION IN PEPTIC ULCER DISEASE PATIENTS IN A TERTIARY CARE HOSPITAL, KURNOOL, ANDHRA PRADESH.”. ijsr 2021. [DOI: 10.36106/ijsr/7029209] [Reference Citation Analysis]
|
| 54 |
Broccoli A, Zinzani PL. How do we sequence therapy for marginal zone lymphomas? Hematology Am Soc Hematol Educ Program 2020;2020:295-305. [PMID: 33275704 DOI: 10.1182/hematology.2020000157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 55 |
Nelson A, Bi Y, Harris D. Helicobacter Pylori: a comprehensive review for primary care providers. Rom J Intern Med 2021;59:112-8. [PMID: 33565305 DOI: 10.2478/rjim-2020-0043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 56 |
Magsi I, Hussain Keerio S, Kumar C, Talpur AS, Shahzeen F, Mushtaq Abbasi Z, Lohano M, Kumar V, Rizwan A. Response of Helicobacter Pylori Eradication Treatment in Patients With Normal and Below-Normal Serum Vitamin D Levels. Cureus 2021;13:e14777. [PMID: 34094742 DOI: 10.7759/cureus.14777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 57 |
Ullah H, Di Minno A, Santarcangelo C, Khan H, Xiao J, Arciola CR, Daglia M. Vegetable Extracts and Nutrients Useful in the Recovery from Helicobacter pylori Infection: A Systematic Review on Clinical Trials. Molecules 2021;26:2272. [PMID: 33919894 DOI: 10.3390/molecules26082272] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 58 |
Ozturk T, Sengul D, Sengul I. Helicobacter pylori and association between its positivity and anatomotopographic settlement in the stomach with the host age range. Ann Afr Med 2021;20:1-8. [PMID: 33727504 DOI: 10.4103/aam.aam_69_19] [Reference Citation Analysis]
|
| 59 |
Qaria MA, Qumar S, Sepe LP, Ahmed N. Cholesterol glucosylation-based survival strategy in Helicobacter pylori. Helicobacter 2021;26:e12777. [PMID: 33368895 DOI: 10.1111/hel.12777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 60 |
Park Y, Kim TJ, Lee H, Yoo H, Sohn I, Min YW, Min BH, Lee JH, Rhee PL, Kim JJ. Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study. Helicobacter 2021;26:e12783. [PMID: 33508177 DOI: 10.1111/hel.12783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 61 |
Liu XZ, Zhang YM, Jia NY, Zhang H. Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy. Ren Fail 2020;42:539-46. [PMID: 32524871 DOI: 10.1080/0886022X.2020.1772295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 62 |
Nkuize M, Vanderpas J, Buset M, Delforge M, Cadière GB, De Wit S. Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Med 2021;22:547-56. [PMID: 33765332 DOI: 10.1111/hiv.13083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 63 |
Kwon TJ, Kim TJ, Lee H, Min YW, Min BH, Lee JH, Kim JJ. Statin Use Decreases the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection. Cancers (Basel) 2021;13:1020. [PMID: 33804425 DOI: 10.3390/cancers13051020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 64 |
Çelik F, Aypak C, Özdemir A, Görpelioğlu S. Inappropriate Prescribing of Proton Pump Inhibitors in Outpatient Clinics. Gastroenterol Nurs 2021;44:84-91. [PMID: 33795619 DOI: 10.1097/SGA.0000000000000500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 65 |
Wu Y, Song Z, Deng G, Jiang K, Wang H, Zhang X, Han H. Gastric Acid Powered Nanomotors Release Antibiotics for In Vivo Treatment of Helicobacter pylori Infection. Small 2021;17:e2006877. [PMID: 33619851 DOI: 10.1002/smll.202006877] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 66 |
Uguen A. Detection of Helicobacter pylori in virtual slides requires high resolution digitalisation. J Clin Pathol 2021:jclinpath-2020-207378. [PMID: 33568425 DOI: 10.1136/jclinpath-2020-207378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 67 |
He XJ, Zeng XP, Jiang CS, Liu G, Li DZ, Wang W. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial. Arab J Gastroenterol 2021;22:47-51. [PMID: 33551347 DOI: 10.1016/j.ajg.2020.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 68 |
Kouitcheu Mabeku LB, Bello Epesse M, Fotsing S, Kamgang R, Tchidjo M. Stool Antigen Testing, a Reliable Noninvasive Method of Assessment of Helicobacter pylori Infection Among Patients with Gastro-duodenal Disorders in Cameroon. Dig Dis Sci 2021;66:511-20. [PMID: 32350723 DOI: 10.1007/s10620-020-06219-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 69 |
Ozturk A. Periodontal Treatment Is Associated With Improvement in Gastric Helicobacter pylori Eradication: An Updated Meta-analysis of Clinical Trials. Int Dent J 2021;71:188-96. [PMID: 34024329 DOI: 10.1111/idj.12616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 70 |
Bakheit AH, Al-Kahtani HM, Albraiki S. Rabeprazole: A comprehensive profile. Profiles Drug Subst Excip Relat Methodol 2021;46:137-83. [PMID: 33461697 DOI: 10.1016/bs.podrm.2020.07.003] [Reference Citation Analysis]
|
| 71 |
Dugan K, Ablah E, Okut H, Srinivasan S, Salyers W Jr. Guideline Adherence in Dyspepsia Investigation and Treatment. Kans J Med 2020;13:306-10. [PMID: 33343824 DOI: 10.17161/kjm.vol13.13838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 72 |
Nelson ND, Tondon R, Fortuna D, Westerhoff M, Swanson PE, Furth E. Helicobacter pylori Antigen But Not the Organism Is Occasionally Present Within Germinal Centers: Implications for Patient Management and Biology. Am J Surg Pathol 2020;44:1528-34. [PMID: 32657781 DOI: 10.1097/PAS.0000000000001542] [Reference Citation Analysis]
|
| 73 |
Klein S, Gildenblat J, Ihle MA, Merkelbach-Bruse S, Noh KW, Peifer M, Quaas A, Büttner R. Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies. BMC Gastroenterol 2020;20:417. [PMID: 33308189 DOI: 10.1186/s12876-020-01494-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 74 |
Jeong HY, Lee TH, Kim JG, Lee S, Moon C, Truong XT, Jeon TI, Moon JH. 3-Pentylcatechol, a Non-Allergenic Urushiol Derivative, Displays Anti-Helicobacter pylori Activity In Vivo. Pharmaceuticals (Basel) 2020;13:E384. [PMID: 33202739 DOI: 10.3390/ph13110384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 75 |
Willems P, de Repentigny J, Hassan GM, Sidani S, Soucy G, Bouin M. The Prevalence of Helicobacter pylori Infection in a Quaternary Hospital in Canada. J Clin Med Res 2020;12:687-92. [PMID: 33224369 DOI: 10.14740/jocmr4348] [Reference Citation Analysis]
|
| 76 |
Zhou S, Marklund H, Blaha O, Desai M, Martin B, Bingham D, Berry GJ, Gomulia E, Ng AY, Shen J. Deep learning assistance for the histopathologic diagnosis of Helicobacter pylori. Intelligence-Based Medicine 2020;1-2:100004. [DOI: 10.1016/j.ibmed.2020.100004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 77 |
Açar S. Helikobakter Pylori Eradikasyonunda Modifiye Hibrit Tedavi Etkinliği. Zeynep Kamil Tıp Bülteni 2020. [DOI: 10.16948/zktipb.773921] [Reference Citation Analysis]
|
| 78 |
Gökışık MT, Uyar S. The role of Helicobacter pylori in vitamin-B(12) deficiency due to metformin use. Helicobacter 2020;25:e12718. [PMID: 32559822 DOI: 10.1111/hel.12718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 79 |
Farhoud NS, Ibrahim OM, Ezzat SE. Efficacy and Cost-effectiveness Comparison of 10-Day, 14-Day Sequential Versus 14-Day Triple Therapies for Treating Helicobacter pylori Infection in Egyptian Patients. J Clin Gastroenterol 2020;54:806-12. [PMID: 31904681 DOI: 10.1097/MCG.0000000000001278] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 80 |
Zare Javid A, Maghsoumi-Norouzabad L, Bazyar H, Aghamohammadi V, Alavinejad P. Effects of Concurrent Omega-3 and Cranberry Juice Consumption Along with Standard Antibiotic Therapy on the Eradication of Helicobacter pylori, Gastrointestinal Symptoms, Some Serum Inflammatory and Oxidative Stress Markers in Adults with Helicobacter pylori Infection: A Study Protocol for a Randomized Controlled Trial. Infect Drug Resist 2020;13:3179-85. [PMID: 32982332 DOI: 10.2147/IDR.S270057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 81 |
Toyoshima O, Nishizawa T, Yoshida S, Sakaguchi Y, Nakai Y, Watanabe H, Suzuki H, Tanikawa C, Matsuda K, Koike K. Endoscopy-based Kyoto classification score of gastritis related to pathological topography of neutrophil activity. World J Gastroenterol 2020; 26(34): 5146-5155 [PMID: 32982115 DOI: 10.3748/wjg.v26.i34.5146] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 82 |
Kim HS, Yoon H, Shin DW, Oh DJ, Kwon M, Choi YJ, Shin CM, Park YS, Kim N, Lee DH. Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2020;20:218-224. [DOI: 10.7704/kjhugr.2020.0021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 83 |
Ryoo SK, Kim TJ, Kim ER, Hong SN, Kim YH, Chang DK. Helicobacter pylori Infection and the Development of Advanced Colorectal Neoplasia. J Clin Gastroenterol 2020;54:696-700. [PMID: 31651570 DOI: 10.1097/MCG.0000000000001273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 84 |
Zhou S, Marklund H, Blaha O, Desai M, Martin B, Bingham D, Berry GJ, Gomulia E, Ng AY, Shen J. Deep learning-based Helicobacter pylori detection for histopathology: A diagnostic study.. [DOI: 10.1101/2020.08.23.20179010] [Reference Citation Analysis]
|
| 85 |
Panarese A, Galatola G, Armentano R, Pimentel-Nunes P, Ierardi E, Caruso ML, Pesce F, Lenti MV, Palmitessa V, Coletta S, Shahini E. Helicobacter pylori-induced inflammation masks the underlying presence of low-grade dysplasia on gastric lesions. World J Gastroenterol 2020; 26(26): 3834-3850 [PMID: 32774061 DOI: 10.3748/wjg.v26.i26.3834] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 86 |
Liu Q, Zhang Y, Xu C, Chen B, Xu H, Cao Y, Guo T, Gao Y, Zhou Z, Zhou X, Xu X, He J. Dentists Are at a Higher Risk for Oral Helicobacter pylori Infection. Biomed Res Int 2020;2020:3945189. [PMID: 32695813 DOI: 10.1155/2020/3945189] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 87 |
Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci 2020;65:1917-31. [PMID: 32170476 DOI: 10.1007/s10620-020-06193-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 14.7] [Reference Citation Analysis]
|
| 88 |
Yoon K, Kim N, Lee JW, Yoon H, Shin CM, Park YS, Lee DH. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter 2020;25:e12685. [PMID: 32141173 DOI: 10.1111/hel.12685] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 89 |
Pu Q, Kazemi M, Mohammadi M. Application of Transition Metals in Sulfoxidation Reactions. MROC 2020;17:423-49. [DOI: 10.2174/1570193x16666190430154835] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 90 |
Kasahun GG, Demoz GT, Desta DM. Primary Resistance Pattern of Helicobacter pylori to Antibiotics in Adult Population: A Systematic Review. Infect Drug Resist 2020;13:1567-73. [PMID: 32547126 DOI: 10.2147/IDR.S250200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 91 |
Evans G, Barker A, Simon L, Kushnir V. High Cost for Low Yield: A Systematic Review and Meta-Analysis to Assess Cost of Routine Preoperative Esophagogastroduodenoscopy Before Bariatric Surgery. J Clin Gastroenterol 2020;54:398-404. [PMID: 32168132 DOI: 10.1097/MCG.0000000000001334] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 92 |
Barton JC, Wiener HH, Acton RT, Adams PC, Eckfeldt JH, Gordeuk VR, Harris EL, McLaren CE, Harrison H, McLaren GD, Reboussin DM. Prevalence of iron deficiency in 62,685 women of seven race/ethnicity groups: The HEIRS Study. PLoS One 2020;15:e0232125. [PMID: 32324809 DOI: 10.1371/journal.pone.0232125] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 93 |
İspiroğlu M, Gişi K, Kantarçeken B. Proton Pompa İnhibitörlerinin Uzun Dönem Kullanımındaki Etkileri. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 2020. [DOI: 10.17517/ksutfd.690248] [Reference Citation Analysis]
|
| 94 |
Rahimi F, Talebi Bezmin Abadi A. Tracking the Virulent Helicobacter pylori Strains Instead of Its Pan-Screening to Prevent Gastric Cancer. BioNanoSci 2020;10:315-317. [DOI: 10.1007/s12668-019-00678-0] [Reference Citation Analysis]
|
| 95 |
Khien VV, Thang DM, Hai TM, Duat NQ, Khanh PH, Ha DT, Binh TT, Dung HDQ, Trang TTH, Yamaoka Y. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver 2019;13:483-97. [PMID: 31009957 DOI: 10.5009/gnl18137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 96 |
Li B, Lan X, Wang L, Zhao J, Ding J, Ding H, Lei J, Wei Y, Zhang W. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis. Microb Pathog 2020;142:104075. [PMID: 32074497 DOI: 10.1016/j.micpath.2020.104075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 97 |
Périco LL, Emílio-Silva MT, Ohara R, Rodrigues VP, Bueno G, Barbosa-Filho JM, Rocha LRMD, Batista LM, Hiruma-Lima CA. Systematic Analysis of Monoterpenes: Advances and Challenges in the Treatment of Peptic Ulcer Diseases. Biomolecules 2020;10:E265. [PMID: 32050614 DOI: 10.3390/biom10020265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 98 |
Jafar M, Mohsin AA, Khalid MS, Alshahrani AM, Alkhateeb FS, Alqarni AS. Ranitidine hydrochloride stomach specific bouyant microsponge: Preparation, in-vitro characterization, and in-vivo anti-ulcer activity. Journal of Drug Delivery Science and Technology 2020;55:101453. [DOI: 10.1016/j.jddst.2019.101453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 99 |
Sezgin O, Aydın MK, Özdemir AA, Kanık AE. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies. Turk J Gastroenterol 2019;30:420-35. [PMID: 31060997 DOI: 10.5152/tjg.2019.18693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 100 |
Maurya VK, Kumar S, Saxena SK. Conventional Treatments of Water-Associated Infectious Diseases. Water-Associated Infectious Diseases 2020. [DOI: 10.1007/978-981-13-9197-2_11] [Reference Citation Analysis]
|
| 101 |
Nasif S, Roshdy R. Role of P53, SOX2, and SOX9 in chronic gastritis, precancerous gastric lesions, and gastric carcinoma in relation to Helicobacter pylori: an immunohistochemical study. Egypt J Pathol 2020;40:187. [DOI: 10.4103/egjp.egjp_9_21] [Reference Citation Analysis]
|
| 102 |
RELATIONSHIP BETWEEN HELICOBACTER PYLORI INFECTION IN TYPE 2 DIABETES MELLITUS PATIENTS BASED ON ANTI IgA AND ANTI IgG HELICOBACTER PYLORI. IJRSM 2020;7:1-5. [DOI: 10.29121/ijrsm.v7.i8.2020.1] [Reference Citation Analysis]
|
| 103 |
Corey BL, Grams JM, Christein JD, Vickers SM. Benign Disease of Stomach and Duodenum. Principles and Practice of Geriatric Surgery 2020. [DOI: 10.1007/978-3-319-47771-8_66] [Reference Citation Analysis]
|
| 104 |
Katzinger J. Biomarkers for Stool Analysis. Textbook of Natural Medicine 2020. [DOI: 10.1016/b978-0-323-43044-9.00028-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 105 |
Herardi R, Syam AF, Simadibrata M, Setiati S, Darnindro N, Abdullah M, Makmun D. Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population: Double-Blinded Randomized Clinical Trial. Asian Pac J Cancer Prev 2020;21:19-24. [PMID: 31983158 DOI: 10.31557/APJCP.2020.21.1.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 106 |
Jacobson-kelly AE, Sharma R, Powers JM. Iron Deficiency Anemia. Hematology in the Adolescent Female 2020. [DOI: 10.1007/978-3-030-48446-0_17] [Reference Citation Analysis]
|
| 107 |
. Chronic abdominal pain in children: the importance of endoscopy. Asian Biomedicine 2019;13:37-8. [DOI: 10.1515/abm-2019-0038] [Reference Citation Analysis]
|
| 108 |
Vitkin VV, Chubchenko IK, Grigorenko KM, Kenzhebaeva Y, Kharitonov AA, Polishchuk AV. Raman Spectroscopy of High-purity 13CO2 Gas. 2019 Photonics & Electromagnetics Research Symposium - Fall (PIERS - Fall) 2019. [DOI: 10.1109/piers-fall48861.2019.9021442] [Reference Citation Analysis]
|
| 109 |
Tang DM, Chascsa DM, Chou JY, Ho N, Auh S, Wank SA, Koh C, Kumar S. Helicobacter pyloriinfection is strongly associated with metabolic syndrome, and weakly associated with non‐alcoholic fatty liver disease, in a US Hispanic population. GastroHep 2019;1:325-331. [DOI: 10.1002/ygh2.375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 110 |
Trung TT, Minh TA, Anh NT. Value of CIM, CLO Test and Multiplex PCR for the Diagnosis of Helicobacter Pylori Infection Status in Patients with Gastritis and Gastric Ulcer. Asian Pac J Cancer Prev 2019;20:3497-503. [PMID: 31759377 DOI: 10.31557/APJCP.2019.20.11.3497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Kane-dumbre S, Momin M, Ravikumar P, Khatri R, RK University, Rajkot- 360 028, Gujarat, India. DRUG DELIVERY STRATEGIES FOR HELICOBACTER PYLORI INFECTION MANAGEMENT: AN OVERVIEW. IND DRU 2019;56:7-21. [DOI: 10.53879/id.56.10.11811] [Reference Citation Analysis]
|
| 112 |
Auttajaroon J, Vilaichone RK, Chotivitayatarakorn P, Mahachai V. Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study). Helicobacter 2019;24:e12615. [PMID: 31282081 DOI: 10.1111/hel.12615] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 113 |
Yuksel Sert S, Ozturk A, Bektas A, Cengiz MI. Periodontal treatment is more effective in gastric Helicobacter pylori eradication in those patients who maintain good oral hygiene. International Dental Journal 2019;69:392-9. [DOI: 10.1111/idj.12484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 114 |
McNicholl AG, O'Morain CA, Megraud F, Gisbert JP; As Scientific Committee of the Hp-Eureg on Behalf of the National Coordinators. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter 2019;24:e12630. [PMID: 31282060 DOI: 10.1111/hel.12630] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 115 |
Sharifi A, Azizi M, Moradi-choghakabodi P, Aghaei S, Azizi A. In vitro anti-Helicobacter pylori activity of aqueous extract from Persian Oak testa. Chinese Herbal Medicines 2019;11:394-9. [DOI: 10.1016/j.chmed.2019.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 116 |
Tseng DS, Li D, Cholleti SM, Wei JC, Jodesty Y, Pham HV. Effect of Helicobacter pylori Treatment on Unexplained Iron Deficiency Anemia. Perm J 2019;23:18-195. [PMID: 30939286 DOI: 10.7812/TPP/18-195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 117 |
Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 118 |
Attia TZ, Yamashita T, Tsujino H, Derayea SM, Tsutsumi Y, Uno T. Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy. Chem Pharm Bull (Tokyo) 2019;67:810-5. [PMID: 31366830 DOI: 10.1248/cpb.c19-00084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 119 |
So HM, Yu JS, Khan Z, Subedi L, Ko YJ, Lee IK, Park WS, Chung SJ, Ahn MJ, Kim SY, Kim KH. Chemical constituents of the root bark of Ulmus davidiana var. japonica and their potential biological activities. Bioorg Chem 2019;91:103145. [PMID: 31357073 DOI: 10.1016/j.bioorg.2019.103145] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 120 |
Delchier JC, Bastuji-Garin S, Raymond J, Megraud F, Amiot A, Cambau E, Burucoa C; HELICOSTIC Study Group. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection. Med Mal Infect. 2020;50:492-499. [PMID: 31257067 DOI: 10.1016/j.medmal.2019.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 121 |
Gebeyehu E, Nigatu D, Engidawork E. Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: A prospective follow up study. PLoS One 2019;14:e0217645. [PMID: 31163069 DOI: 10.1371/journal.pone.0217645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 122 |
Laredo V, Sostres C, Alfaro E, Arroyo MT, Lanas Á. Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates. Helicobacter 2019;24:e12586. [PMID: 30950147 DOI: 10.1111/hel.12586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 123 |
Kwon YJ, Kim N, Baek SM, Lee HS, Lee J, Hwang YJ, Yoon H, Shin CM, Park YS, Kim JW, Lee DH. The prevalence of histologic atrophy and intestinal metaplasia in the corpus has decreased over 15 years in females in the Korean population. Helicobacter 2019;24:e12579. [PMID: 30920087 DOI: 10.1111/hel.12579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 124 |
Richter V, Gonzalez JO, Hazan S, Gottlieb G, Friedenberg K, Gatof D, Ganeshappa R, Delgado JS, Abramowitz D, Hardi R, Coates A, Haq M, Mehta N, Jones BA, Moss SF, Shirin H. The validity of breath collection bags method in detecting Helicobacter pylori using the novel BreathID ® Hp Lab System: a multicenter clinical study in 257 subjects. Ther Adv Gastrointest Endosc 2019;12:2631774519843401. [PMID: 31192315 DOI: 10.1177/2631774519843401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 125 |
Fan F, Wang Z, Li B, Zhang H. Effects of eradicating Helicobacter pylori on metachronous gastric cancer prevention: A systematic review and meta‐analysis. J Eval Clin Pract 2019;26:308-15. [DOI: 10.1111/jep.13179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 126 |
Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. Biomed Res Int 2019;2019:9781212. [PMID: 31211144 DOI: 10.1155/2019/9781212] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 127 |
Khalil AAK, Park WS, Lee J, Kim HJ, Akter KM, Goo YM, Bae JY, Chun MS, Kim JH, Ahn MJ. A new anti-Helicobacter pylori juglone from Reynoutria japonica. Arch Pharm Res 2019;42:505-11. [PMID: 31073878 DOI: 10.1007/s12272-019-01160-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 128 |
Ioannidou P, Papanikolaou D, Mikos T, Mastorakos G, Goulis DG. Predictive factors of Hyperemesis Gravidarum: A systematic review. Eur J Obstet Gynecol Reprod Biol 2019;238:178-87. [PMID: 31126753 DOI: 10.1016/j.ejogrb.2019.04.043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 129 |
Kumral TL, Gökden Y, Saltürk Z, Berkiten G, Yıldırım G, Ataç E, Tutar B, Uyar Y. The Effect of Gastric Helicobacter pylori Colonization on Nasal Functions. Ear Nose Throat J 2019;98:346-50. [PMID: 31018689 DOI: 10.1177/0145561319840825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 130 |
Tran VH. EFFICACY OF MODIFIED BISMUTH QUADRUPLE THERAPY (RBMA) AS FIRST-LINE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH CHRONIC GASTRITIS. JMP 2019. [DOI: 10.34071/jmp.2019.2.5] [Reference Citation Analysis]
|
| 131 |
Bayati S, Amirmozafari N, Alebouyeh M, Farzi N, Ebrahimi Daryani N, Zali MR. Antibiotic Resistance Among Helicobacter pylori Strains Isolated from Patients with Gastric Pathologies Towards Metronidazole, Clarithromycin, and Ciprofloxacin. Arch Clin Infect Dis 2019;In Press. [DOI: 10.5812/archcid.55015] [Reference Citation Analysis]
|
| 132 |
Ennkaa A, Shaath N, Salam A, Mohammad RM. Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study. Turk J Gastroenterol 2018;29:549-54. [PMID: 30260776 DOI: 10.5152/tjg.2018.17707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 133 |
Kohler V, Vaishampayan A, Grohmann E. Problematic Groups of Multidrug-Resistant Bacteria and Their Resistance Mechanisms. Antibacterial Drug Discovery to Combat MDR 2019. [DOI: 10.1007/978-981-13-9871-1_2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 134 |
Li C, Ellsmere J. Diagnostic and Therapeutic Endoscopy of the Stomach and Small Bowel. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00057-1] [Reference Citation Analysis]
|
| 135 |
Mannon PJ. Immunological Diseases of the Gastrointestinal Tract. Clinical Immunology. Elsevier; 2019. pp. 1005-1019.e1. [DOI: 10.1016/b978-0-7020-6896-6.00075-2] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 136 |
Gambitta P, Bareggi E, Iannuzzi F, Conte DL, D’alessandro A, Ballerini A, Pallotta S, Armellino A, Aseni P. Updates in Gastrointestinal Emergencies: Inflammatory Conditions and Obstructions. Operative Techniques and Recent Advances in Acute Care and Emergency Surgery 2019. [DOI: 10.1007/978-3-319-95114-0_29] [Reference Citation Analysis]
|
| 137 |
Lee KH, Park SY, Jeong SJ, Jung DH, Kim JH, Jeong SH, Kang IM, Song YG. Can Aminoglycosides Be Used as a New Treatment for Helicobacter pylori? In vitro Activity of Recently Isolated Helicobacter pylori. Infect Chemother 2019;51:10-20. [PMID: 30941933 DOI: 10.3947/ic.2019.51.1.10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 138 |
Baiu I, Azagury DE. Risk Factor Modification in Patients with Peptic Ulcer Disease. The SAGES Manual of Foregut Surgery 2019. [DOI: 10.1007/978-3-319-96122-4_54] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 139 |
Kayali S, Aloe R, Bonaguri C, Gaiani F, Manfredi M, Leandro G, Fornaroli F, Di Mario F, De' Angelis GL. Non-invasive tests for the diagnosis of helicobacter pylori: state of the art. Acta Biomed 2018;89:58-64. [PMID: 30561419 DOI: 10.23750/abm.v89i8-S.7910] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
|
| 140 |
Helicobacter pylori. Infectious Causes of Cancer 2018. [DOI: 10.1002/9780470753651.ch11] [Reference Citation Analysis]
|
| 141 |
Feder R, Posner S, Qin Y, Zheng J, Chow SC, Garman KS. Helicobacter pylori-associated peptic ulcer disease: A retrospective analysis of post-treatment testing practices. Helicobacter 2018;23:e12540. [PMID: 30246287 DOI: 10.1111/hel.12540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 142 |
Yun CY, Kim N, Lee J, Lee JY, Hwang YJ, Lee HS, Yoon H, Shin CM, Park YS, Kim JW, Lee DH. Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors. Helicobacter 2018;23:e12542. [PMID: 30303591 DOI: 10.1111/hel.12542] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 143 |
Son JH, Lebwohl B, Sepulveda AR, Lagana SM. Utilization Rate of Helicobacter pylori Immunohistochemistry Is Not Associated With the Diagnostic Rate of Helicobacter pylori Infection. Appl Immunohistochem Mol Morphol 2019;27:694-8. [PMID: 30499817 DOI: 10.1097/PAI.0000000000000680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 144 |
Kitila KT, Sori LM, Desalegn DM, Tullu KD. Burden of Helicobacter pylori Infections and Associated Risk Factors among Women of Child Bearing Age in Addis Ababa, Ethiopia. Int J Chronic Dis 2018;2018:5183713. [PMID: 30538998 DOI: 10.1155/2018/5183713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 145 |
Sabbagh P, Mohammadnia-afrouzi M, Javanian M, Babazadeh A, Koppolu V, Vasigala VR, Nouri HR, Ebrahimpour S. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations. Eur J Clin Microbiol Infect Dis 2019;38:55-66. [DOI: 10.1007/s10096-018-3414-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 146 |
Leow AH, Azmi AN, Loke MF, Vadivelu J, Graham DY, Goh KL. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis 2018;19:674-7. [PMID: 30307122 DOI: 10.1111/1751-2980.12679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 147 |
Auesomwang C, Maneerattanaporn M, Chey WD, Kiratisin P, Leelakusolwong S, Tanwandee T. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication. J Gastroenterol Hepatol 2018;33:1822-8. [PMID: 29804294 DOI: 10.1111/jgh.14292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 148 |
Ali E, Arshad N, Bukhari NI, Nawaz Tahir M, Zafar S, Hussain A, Parveen S, Qamar S, Shehzadi N, Hussain K. Linking traditional anti-ulcer use of rhizomes of Bergenia ciliata (Haw.) to its anti-Helicobacter pylori constituents. Nat Prod Res 2020;34:541-4. [PMID: 30362366 DOI: 10.1080/14786419.2018.1488711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 149 |
Ozaki H, Harada S, Takeuchi T, Kawaguchi S, Takahashi Y, Kojima Y, Ota K, Hongo Y, Ashida K, Sakaguchi M, Tokioka S, Sakamoto H, Furuta T, Tominaga K, Higuchi K. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Digestion 2018;97:212-8. [PMID: 29393194 DOI: 10.1159/000485097] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 150 |
Zhou Y, Ouyang L, Yi X, Gan T, Qi J, Wan Y, Wang Y, An S, Shi Y, Yang W, Chen W, Luo Z, Li J, Luo J, Nuertai X, Zhu X, Yang F, Zhao B, Zhang W, Ye Z, Zhang X, Weng S, Liu Q, Cao W, He J. Microbial Cells Harboring a Mitochondrial Gene Are Capable of CO2 Capture.. [DOI: 10.1101/411090] [Reference Citation Analysis]
|
| 151 |
Yousefi-avarvand A, Vaez H, Tafaghodi M, Sahebkar AH, Arzanlou M, Khademi F. Antibiotic Resistance of Helicobacter pylori in Iranian Children: A Systematic Review and Meta-Analysis. Microbial Drug Resistance 2018;24:980-6. [DOI: 10.1089/mdr.2017.0292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 152 |
Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 2018;14:111-7. [DOI: 10.1016/j.jgar.2018.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 153 |
Chen Y, Lin K, Wang H, Yu H, Tsai K, Hsu P. The efficacies of esomeprazole- versus pantoprazole-based reverse hybrid therapy for Helicobacter pylori eradication. Adv Dig Med 2018;5:26-32. [DOI: 10.1002/aid2.13070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 154 |
Lopetuso LR, Napoli M, Rizzatti G, Scaldaferri F, Franceschi F, Gasbarrini A. Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2018;12:899-906. [PMID: 30040500 DOI: 10.1080/17474124.2018.1503946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 155 |
El Shahawy MS, Hemida MH, El Metwaly I, Shady ZM. The effect of vitamin D deficiency on eradication rates of Helicobacter pylori infection. JGH Open 2018;2:270-5. [PMID: 30619936 DOI: 10.1002/jgh3.12081] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 156 |
Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'Brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost 2018;16:1656-64. [PMID: 29978552 DOI: 10.1111/jth.14192] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 157 |
Hussain A, Tabrez E, Peela J, Honnavar P Dr, Tabrez SSM. Vitamin C: A Preventative, Therapeutic Agent Against Helicobacter pylori. Cureus 2018;10:e3062. [PMID: 30280058 DOI: 10.7759/cureus.3062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 158 |
El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe SE, Elfant A, Haas T, Hapke RJ, Graham DY. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol 2018;16:992-1002.e6. [PMID: 29559361 DOI: 10.1016/j.cgh.2018.03.013] [Cited by in Crossref: 118] [Cited by in F6Publishing: 96] [Article Influence: 23.6] [Reference Citation Analysis]
|
| 159 |
Mera RM, Bravo LE, Camargo MC, Bravo JC, Delgado AG, Romero-Gallo J, Yepez MC, Realpe JL, Schneider BG, Morgan DR, Peek RM Jr, Correa P, Wilson KT, Piazuelo MB. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut 2018;67:1239-46. [PMID: 28647684 DOI: 10.1136/gutjnl-2016-311685] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 18.8] [Reference Citation Analysis]
|
| 160 |
Caicedo Ochoa EY, Quintero Moreno CO, Méndez Fandiño YR, Sánchez Fonseca SC, Cortes Motta HF, Guio Guerra SA. Assessment of the use of vitamin C and E supplements concomitantly to antibiotic treatment against Helicobacter pylori : A systematic review and meta-analysis. Medicina Clínica (English Edition) 2018;151:45-52. [DOI: 10.1016/j.medcle.2018.05.016] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 161 |
Tonkic A, Vukovic J, Vrebalov Cindro P, Pesutic Pisac V, Tonkic M. Diagnosis of Helicobacter pylori infection : A short review. Wien Klin Wochenschr 2018;130:530-4. [PMID: 29959527 DOI: 10.1007/s00508-018-1356-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 162 |
Fahimi F, Sarhaddi S, Fouladi M, Samadi N, Sadeghi J, Golchin A, Tohidkia MR, Barar J, Omidi Y. Phage display-derived antibody fragments against conserved regions of VacA toxin of Helicobacter pylori. Appl Microbiol Biotechnol 2018;102:6899-913. [PMID: 29862446 DOI: 10.1007/s00253-018-9068-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 163 |
Vilaichone RK, Quach DT, Yamaoka Y, Sugano K, Mahachai V. Prevalence and Pattern of Antibiotic Resistant Strains of Helicobacter Pylori Infection in ASEAN. Asian Pac J Cancer Prev 2018;19:1411-3. [PMID: 29802708 DOI: 10.22034/APJCP.2018.19.5.1411] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
|
| 164 |
Talebi Bezmin Abadi A. Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches. J Pathog 2018;2018:9064952. [PMID: 29951318 DOI: 10.1155/2018/9064952] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 165 |
Szadkowski A, Zemlak M, Muszyński J. Effectiveness of Helicobacter pylori eradication established on the basis of examination of antibiotic resistance of the bacteria. Prz Gastroenterol 2018;13:93-8. [PMID: 30002766 DOI: 10.5114/pg.2018.75821] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 166 |
Shapla UM, Raihan J, Islam A, Alam F, Solayman N, Gan SH, Hossen S, Khalil I. Propolis: The future therapy against Helicobacter pylori-mediated gastrointestinal diseases. J Appl Biomed 2018;16:81-99. [DOI: 10.1016/j.jab.2017.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 167 |
Mukherjee S, Jana T, Pan JJ. Adverse Effects of Proton Pump Inhibitors on Platelet Count: A Case Report and Review of the Literature. Case Rep Gastrointest Med 2018;2018:4294805. [PMID: 29854491 DOI: 10.1155/2018/4294805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 168 |
Pintar T, Kaliterna N, Carli T. The need for a patient-tailored Helicobacter pylori eradication protocol prior to bariatric surgery. J Int Med Res 2018;46:2696-707. [PMID: 29690823 DOI: 10.1177/0300060518769543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 169 |
Zhang X, Jiang A, Qi B, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori. Appl Microbiol Biotechnol 2018;102:4817-27. [DOI: 10.1007/s00253-018-8982-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 170 |
Denlinger NM, Epperla N, William BM. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Manag Res 2018;10:615-24. [PMID: 29628774 DOI: 10.2147/CMAR.S133291] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 171 |
Best LM, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, Yaghoobi M, Gurusamy KS. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3:CD012080. [PMID: 29543326 DOI: 10.1002/14651858.cd012080.pub2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 172 |
Suzuki J, Shimazaki K, Koike S, Ono T. Gastric emptying rate before and after orthodontic treatment examined with the [13C] breath test: A pilot study. Am J Orthod Dentofacial Orthop 2018;153:347-54. [PMID: 29501109 DOI: 10.1016/j.ajodo.2017.06.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 173 |
Negash M, Kassu A, Amare B, Yismaw G, Moges B. Evaluation of SD BIOLINE H. pylori Ag rapid test against double ELISA with SD H. pylori Ag ELISA and EZ-STEP H. pylori Ag ELISA tests. BMC Clin Pathol 2018;18:4. [PMID: 29515332 DOI: 10.1186/s12907-018-0071-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 174 |
Lee M, Baek H, Park JS, Kim S, Kyung C, Baik SJ, Lee BK, Kim JH, Ahn CW, Kim KR, Kang S. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study. PLoS One 2018;13:e0193646. [PMID: 29499055 DOI: 10.1371/journal.pone.0193646] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 175 |
Mwafy SN, Afana WM. Hematological parameters, serum iron and vitamin B12 levels in hospitalized Palestinian adult patients infected with Helicobacter pylori: a case-control study. Hematol Transfus Cell Ther. 2018;40:160-165. [PMID: 30057990 DOI: 10.1016/j.htct.2017.11.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 176 |
Nastoupil LJ, Koff JL, Bernal-mizrachi L, Flowers CR. Non-Hodgkin Lymphoma in Adults. The American Cancer Society's Oncology in Practice 2018. [DOI: 10.1002/9781118592168.ch32] [Reference Citation Analysis]
|
| 177 |
John S, Baltodano JD, Mehta N, Mark K, Murthy U. Unexplained iron deficiency anemia: does Helicobacter pylori have a role to play? Gastroenterol Rep (Oxf) 2018;6:215-20. [PMID: 30151206 DOI: 10.1093/gastro/goy001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 178 |
Hwang YJ, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther 2018;47:380-90. [PMID: 29193217 DOI: 10.1111/apt.14424] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 20.8] [Reference Citation Analysis]
|
| 179 |
Nayar DS. Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. Infect Drug Resist 2018;11:205-11. [PMID: 29430191 DOI: 10.2147/IDR.S153617] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 180 |
Yilmaz B, Koseoglu H, Coskun Y, Deveci M, Kekilli M. Comparison between different first-line therapy protocols in eradicating Helicobacter pylori in a region with high clarithromycin resistance. Prz Gastroenterol 2018;13:150-6. [PMID: 30002775 DOI: 10.5114/pg.2018.72732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 181 |
Huerta-Franco MR, Banderas JW, Allsworth JE. Ethnic/racial differences in gastrointestinal symptoms and diagnosis associated with the risk of Helicobacter pylori infection in the US. Clin Exp Gastroenterol 2018;11:39-49. [PMID: 29403299 DOI: 10.2147/CEG.S144967] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 182 |
. High-Risk Pregnancy. 2018. [DOI: 10.1017/9781108349185] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 183 |
Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut 2018;67:20-7. [PMID: 27670375 DOI: 10.1136/gutjnl-2016-311868] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 184 |
Overbey DM, Jones EL. Acid Peptic Ulcer Disease. Abernathy's Surgical Secrets 2018. [DOI: 10.1016/b978-0-323-47873-1.00047-4] [Reference Citation Analysis]
|
| 185 |
Sepulveda AR, J. Del Portillo A. Molecular Basis of Diseases of the Gastrointestinal Tract. Molecular Pathology 2018. [DOI: 10.1016/b978-0-12-802761-5.00019-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 186 |
Bakry OA, Basha M, El Hefnawy S, Mekkawy S. Relationship between Disease Activity and Helicobacter pylori Infection in Patients with Vitiligo. Indian Dermatol Online J 2018;9:59-61. [PMID: 29441304 DOI: 10.4103/idoj.IDOJ_77_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 187 |
Huh CW, Kim B. Diagnosis of Helicobacter pylori Infection. Korean J Gastroenterol 2018;72:229. [DOI: 10.4166/kjg.2018.72.5.229] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 188 |
Ramírez FB, Núñez CG, Tejero Mas M, Rivera Jiménez N, Pérez Caballero FL. Criterios para la erradicación de Helicobacter pylori. FMC - Formación Médica Continuada en Atención Primaria 2018;25:43-53. [DOI: 10.1016/j.fmc.2017.03.009] [Reference Citation Analysis]
|
| 189 |
Campbell S, Landry ML. Rapid Microbial Antigen Tests. Advanced Techniques in Diagnostic Microbiology 2018. [DOI: 10.1007/978-3-319-33900-9_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 190 |
Kubra Hussaini SZ, Humaira Hussaini SZ, Yasmeen R, Unnisa B, Syed AAA, Khan MN, Hassan SI. Comparison of efficacy and pharmacoeconomics of two Helicobacter pylori eradication regimens in peptic ulcer disease. Perspect Clin Res 2018;9:4-8. [PMID: 29430411 DOI: 10.4103/picr.PICR_99_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 191 |
Dougherty MK, Santoiemma PP, Weber AT, Metz DC, Yang YX. Low yield for non-targeted biopsies of the stomach and esophagus during elective esophagogastroduodenoscopy. Endosc Int Open 2017;5:E1268-77. [PMID: 29218319 DOI: 10.1055/s-0043-119791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 192 |
Prasad MA, Friedman LS. Peptic Ulcer Disease. Sitaraman and Friedman's Essentials of Gastroenterology 2017. [DOI: 10.1002/9781119235170.ch3] [Reference Citation Analysis]
|
| 193 |
Caicedo Ochoa EY, Quintero Moreno CO, Méndez Fandiño YR, Sánchez Fonseca SC, Cortes Motta HF, Guio Guerra SA. Assessment of the use of vitamin C and E supplements concomitantly to antibiotic treatment against Helicobacter pylori: A systematic review and meta-analysis. Med Clin (Barc) 2018;151:45-52. [PMID: 29102269 DOI: 10.1016/j.medcli.2017.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 194 |
Kale-pradhan P, Wilhelm S. Chapter 20: Prebiotics and Probiotics. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 19th Edition 2017. [DOI: 10.21019/9781582122656.ch20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 195 |
Chotivitayatarakorn P, Mahachai V, Vilaichone RK. Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev 2017;18:2839-43. [PMID: 29072432 DOI: 10.22034/APJCP.2017.18.10.2839] [Reference Citation Analysis]
|
| 196 |
Grišin E, Mikalauskas S, Poškus T, Jotautas V, Strupas K. Laparoscopic pyloroplasty for perforated peptic ulcer. Wideochir Inne Tech Maloinwazyjne 2017;12:311-4. [PMID: 29062455 DOI: 10.5114/wiitm.2017.68537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 197 |
Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Antimicrob Agents Chemother 2017;61:e00140-17. [PMID: 28807915 DOI: 10.1128/AAC.00140-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 198 |
Wang Y, Zhao R, Wang B, Zhao Q, Li Z, Zhu-ge L, Yin W, Xie Y. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1-13. [DOI: 10.1007/s00228-017-2347-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 199 |
Chubchenko YK, Konopel’ko LA. Features of Determining the Isotope Composition of Carbon in Gaseous, Liquid, and Solid Media. Meas Tech 2017;60:638-42. [DOI: 10.1007/s11018-017-1248-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 200 |
Ginestet F, Guibourg B, Doucet L, Théreaux J, Robaszkiewicz M, Marcorelles P, Uguen A. Upfront immunohistochemistry improves specificity of Helicobacter pylori diagnosis. A French pathology laboratory point of view. Helicobacter 2017;22. [PMID: 28799687 DOI: 10.1111/hel.12424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 201 |
Olsen M. Malpresentation. Obstetric Care 2017. [DOI: 10.1017/9781316662571.021] [Reference Citation Analysis]
|
| 202 |
Hamdi M. Diabetes Mellitus in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.044] [Reference Citation Analysis]
|
| 203 |
Casey F. Second Trimester Pregnancy Loss. Obstetric Care 2017. [DOI: 10.1017/9781316662571.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 204 |
Bjorkman DJ, Steenblik M. Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. Curr Treat Options Gastroenterol 2017;15:648-59. [PMID: 28932965 DOI: 10.1007/s11938-017-0157-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 205 |
Davis GH. The History of Obstetrics. Obstetric Care 2017. [DOI: 10.1017/9781316662571.054] [Reference Citation Analysis]
|
| 206 |
Williford AE. Intraamniotic Infection. Obstetric Care 2017. [DOI: 10.1017/9781316662571.022] [Reference Citation Analysis]
|
| 207 |
Peterson JE. Connective Tissue Disorders and Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.045] [Reference Citation Analysis]
|
| 208 |
Petruska S. Vaginal Birth after Cesarean. Obstetric Care 2017. [DOI: 10.1017/9781316662571.010] [Reference Citation Analysis]
|
| 209 |
Ladson GM, Looney KR, Jackson S. Disability in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.053] [Reference Citation Analysis]
|
| 210 |
Anaya H, Betz A. Prenatal Diagnosis. Obstetric Care 2017. [DOI: 10.1017/9781316662571.016] [Reference Citation Analysis]
|
| 211 |
Davis GH. Operative Vaginal Delivery. Obstetric Care 2017. [DOI: 10.1017/9781316662571.007] [Reference Citation Analysis]
|
| 212 |
Graves CR. Cardiovascular Disease in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.037] [Reference Citation Analysis]
|
| 213 |
Canela C. Shoulder Dystocia. Obstetric Care 2017. [DOI: 10.1017/9781316662571.011] [Reference Citation Analysis]
|
| 214 |
Newman L, Frey H. Placental Abnormalities. Obstetric Care 2017. [DOI: 10.1017/9781316662571.005] [Reference Citation Analysis]
|
| 215 |
Stockdale CK, Martini S. Dermatologic Disorders and Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.046] [Reference Citation Analysis]
|
| 216 |
Rotholz S, Galan HL. Obstetric Ultrasound for the Generalist Obstetrician. Obstetric Care 2017. [DOI: 10.1017/9781316662571.015] [Reference Citation Analysis]
|
| 217 |
Decesare JZ. Postpartum Hemorrhage. Obstetric Care 2017. [DOI: 10.1017/9781316662571.029] [Reference Citation Analysis]
|
| 218 |
Rigby FB. Multifetal Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.023] [Reference Citation Analysis]
|
| 219 |
Beasley A. Fetal Anomalies. Obstetric Care 2017. [DOI: 10.1017/9781316662571.020] [Reference Citation Analysis]
|
| 220 |
Beausang JK, Cooper SM. Obesity in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.034] [Reference Citation Analysis]
|
| 221 |
Shaffer S, Stockdale CK. Musculoskeletal Disorders. Obstetric Care 2017. [DOI: 10.1017/9781316662571.033] [Reference Citation Analysis]
|
| 222 |
Standifer R, Garrison EA. Abnormal Labor. Obstetric Care 2017. [DOI: 10.1017/9781316662571.003] [Reference Citation Analysis]
|
| 223 |
Akinlaja O, Gist W. Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum. Obstetric Care 2017. [DOI: 10.1017/9781316662571.035] [Reference Citation Analysis]
|
| 224 |
Antoniewicz LW, Schneider KM. Neurological Disease Complicating Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.039] [Reference Citation Analysis]
|
| 225 |
Goldberg A. Induction and Augmentation of Labor. Obstetric Care 2017. [DOI: 10.1017/9781316662571.004] [Reference Citation Analysis]
|
| 226 |
Jackson JR, Decesare J. Antepartum Hemorrhage. Obstetric Care 2017. [DOI: 10.1017/9781316662571.028] [Reference Citation Analysis]
|
| 227 |
. Obstetric Care. 2017. [DOI: 10.1017/9781316662571] [Reference Citation Analysis]
|
| 228 |
Altizer MD. Cesarean Delivery Complications and Cesarean Hysterectomy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.009] [Reference Citation Analysis]
|
| 229 |
Ferrell G. Intrapartum Fetal Monitoring. Obstetric Care 2017. [DOI: 10.1017/9781316662571.014] [Reference Citation Analysis]
|
| 230 |
Patrick SK, Schneider KM. Gastrointestinal Disorders in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.042] [Reference Citation Analysis]
|
| 231 |
Chen KK. Selected Endocrine Disorders in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.043] [Reference Citation Analysis]
|
| 232 |
Churchill D, Moussa M. Postpartum Infection. Obstetric Care 2017. [DOI: 10.1017/9781316662571.030] [Reference Citation Analysis]
|
| 233 |
Elson M. Selected Infectious Diseases. Obstetric Care 2017. [DOI: 10.1017/9781316662571.047] [Reference Citation Analysis]
|
| 234 |
Coyne L, Stockdale CK. Hypertension in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.036] [Reference Citation Analysis]
|
| 235 |
Welt SI. Genetics. Obstetric Care 2017. [DOI: 10.1017/9781316662571.017] [Reference Citation Analysis]
|
| 236 |
. Preface. Obstetric Care 2017. [DOI: 10.1017/9781316662571.001] [Reference Citation Analysis]
|
| 237 |
Bressman PL. Management of Obstetric Umbilical Cord Complications. Obstetric Care 2017. [DOI: 10.1017/9781316662571.006] [Reference Citation Analysis]
|
| 238 |
Leftwich H. Abnormal Fetal Growth. Obstetric Care 2017. [DOI: 10.1017/9781316662571.018] [Reference Citation Analysis]
|
| 239 |
Raughley MJ, La Monica G. Renal Diseases in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.040] [Reference Citation Analysis]
|
| 240 |
Hoffman MC, Hamalian G. Psychiatric Diseases in Pregnancy and the Postpartum Period. Obstetric Care 2017. [DOI: 10.1017/9781316662571.049] [Reference Citation Analysis]
|
| 241 |
Kuhlmann ZC. Thromboembolic Complications of Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.052] [Reference Citation Analysis]
|
| 242 |
Tsaltas T. Cesarean Section. Obstetric Care 2017. [DOI: 10.1017/9781316662571.008] [Reference Citation Analysis]
|
| 243 |
Richard SD, Veselis CA. Cancer in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.051] [Reference Citation Analysis]
|
| 244 |
Bowersox N. Hematologic Diseases Complicating Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.041] [Reference Citation Analysis]
|
| 245 |
Garrison EA. Normal Labor. Obstetric Care 2017. [DOI: 10.1017/9781316662571.002] [Reference Citation Analysis]
|
| 246 |
Roche NE, Oparaji DC. Substance Use in Women and Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.050] [Reference Citation Analysis]
|
| 247 |
Vrees RA. Preterm Delivery. Obstetric Care 2017. [DOI: 10.1017/9781316662571.025] [Reference Citation Analysis]
|
| 248 |
Martinez A. Perineal Trauma after Vaginal Delivery: Third and Fourth Degree Lacerations and Hematomas. Obstetric Care 2017. [DOI: 10.1017/9781316662571.012] [Reference Citation Analysis]
|
| 249 |
Akinlaja O, Gist W. Post-term Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.032] [Reference Citation Analysis]
|
| 250 |
Lagow J. Premature Rupture of Fetal Membranes Preterm and at Term. Obstetric Care 2017. [DOI: 10.1017/9781316662571.024] [Reference Citation Analysis]
|
| 251 |
Rebele EC. Third Trimester Fetal Loss. Obstetric Care 2017. [DOI: 10.1017/9781316662571.027] [Reference Citation Analysis]
|
| 252 |
Campbell JP, Plaat F. Obstetric Anesthesia. Obstetric Care 2017. [DOI: 10.1017/9781316662571.013] [Reference Citation Analysis]
|
| 253 |
Goodnight W, Olsen M. Alloimmunization and Non-immune Hydrops Fetalis. Obstetric Care 2017. [DOI: 10.1017/9781316662571.019] [Reference Citation Analysis]
|
| 254 |
Shumway J, Babarinsa I. Pulmonary Disease in Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.038] [Reference Citation Analysis]
|
| 255 |
Plaat F, Cox C. The Obstetric Patient with Trauma. Obstetric Care 2017. [DOI: 10.1017/9781316662571.031] [Reference Citation Analysis]
|
| 256 |
Willers D. Human Immunodeficiency Virus Infection and Pregnancy. Obstetric Care 2017. [DOI: 10.1017/9781316662571.048] [Reference Citation Analysis]
|
| 257 |
Can ME, Kaplan FE, Uzel MM, Kiziltoprak H, Ergun MC, Koc M, Simsek G. The association of Helicobacter pylori with choroidal and retinal nerve fiber layer thickness. Int Ophthalmol 2018;38:1915-22. [PMID: 28780617 DOI: 10.1007/s10792-017-0677-1] [Reference Citation Analysis]
|
| 258 |
Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, Das R, Lu H, Lin JT, Tu YK. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707-715. [PMID: 28781119 DOI: 10.1016/s2468-1253(17)30219-4] [Cited by in Crossref: 138] [Cited by in F6Publishing: 150] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 259 |
Dacoll C, Sánchez-delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay. Gastroenterología y Hepatología (English Edition) 2017;40:447-454. [DOI: 10.1016/j.gastre.2017.07.007] [Reference Citation Analysis]
|
| 260 |
Dacoll C, Sánchez-delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay. Gastroenterología y Hepatología 2017;40:447-54. [DOI: 10.1016/j.gastrohep.2017.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 261 |
Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter 2017;22. [PMID: 28425141 DOI: 10.1111/hel.12389] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 262 |
Yoon H, Lee DH, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Kim JW, Jeong SH, Kim N. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. Gut Liver 2016;10:520-5. [PMID: 26347514 DOI: 10.5009/gnl15048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 263 |
Kim JS, Kim BW, Hong SJ, Kim JI, Shim KN, Kim JH, Baik GH, Kim SW, Song HJ, Kim JH. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. Gut Liver. 2016; Apr 28. [Epub ahead of print]. [PMID: 27114421 DOI: 10.5009/gnl15470] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 264 |
Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 2017;46:106-14. [PMID: 28497487 DOI: 10.1111/apt.14130] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
|
| 265 |
Rhodes LA PharmD. Practical considerations for managing Helicobacter pylori in college health. J Am Coll Health 2017;65:361-2. [PMID: 28622096 DOI: 10.1080/07448481.2017.1341901] [Reference Citation Analysis]
|
| 266 |
Shuto M, Fujioka T, Matsunari O, Okamoto K, Mizukami K, Okimoto T, Kodama M, Takigami S, Seguchi C, Nonaka Y, Sato R, Yamaoka Y, Murakami K. Association between Gastric Cancer Risk and Serum Helicobacter pylori Antibody Titers. Gastroenterol Res Pract 2017;2017:1286198. [PMID: 28690637 DOI: 10.1155/2017/1286198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 267 |
Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI, Chang CC, Chang WL, Lin JT. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter 2017;22. [PMID: 28066960 DOI: 10.1111/hel.12368] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 268 |
Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. Arab Journal of Gastroenterology 2017;18:62-7. [DOI: 10.1016/j.ajg.2017.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 269 |
Chuah YY, Wu DC, Chuah SK, Yang JC, Lee TH, Yeh HZ, Chen CL, Liu YH, Hsu PI. Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey). Helicobacter 2017;22. [PMID: 28244264 DOI: 10.1111/hel.12380] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 270 |
Wang L, Lin Z, Chen S, Li J, Chen C, Huang Z, Ye B, Ding J, Li W, Wu L, Jiang Y, Meng L, Du Q, Si J. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori –related chronic gastritis: a prospective randomized study in China. Clinical Microbiology and Infection 2017;23:391-5. [DOI: 10.1016/j.cmi.2016.12.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 271 |
Abu-Sini M, Mayyas A, Al-Karablieh N, Darwish R, Al-Hiari Y, Aburjai T, Arabiyat S, Abu-Qatouseh L. Synthesis of 1,2,3-Triazolo[4,5-h]quinolone Derivatives with Novel Anti-Microbial Properties against Metronidazole Resistant Helicobacter pylori. Molecules 2017;22:E841. [PMID: 28531095 DOI: 10.3390/molecules22050841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 272 |
Miftahussurur M, Nusi IA, Akil F, Syam AF, Wibawa IDN, Rezkitha YAA, Maimunah U, Subsomwong P, Parewangi ML, Mariadi IK, Adi P, Uchida T, Purbayu H, Sugihartono T, Waskito LA, Hidayati HB, Lusida MI, Yamaoka Y. Gastric mucosal status in populations with a low prevalence of Helicobacter pylori in Indonesia. PLoS One 2017;12:e0176203. [PMID: 28463979 DOI: 10.1371/journal.pone.0176203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 273 |
Abadi ATB. Strategies used by helicobacter pylori to establish persistent infection. World J Gastroenterol 2017; 23(16): 2870-2882 [PMID: 28522905 DOI: 10.3748/wjg.v23.i16.2870] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 274 |
Murakami TT, Scranton RA, Brown HE, Harris RB, Chen Z, Musuku S, Oren E. Management of Helicobacter Pylori in the United States: Results from a national survey of gastroenterology physicians. Prev Med 2017;100:216-22. [PMID: 28457713 DOI: 10.1016/j.ypmed.2017.04.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 275 |
Geng X, Li W, Chen Z, Gao S, Hong W, Ge X, Hou G, Hu Z, Zhou Y, Zeng B, Li W, Jia J, Sun Y. The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. Antimicrob Agents Chemother 2017;61:e02011-16. [PMID: 28242673 DOI: 10.1128/AAC.02011-16] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 276 |
Ebrahem R, Kadhem S, Frey JW, Salyers W. Endoscopic View of Gastroduodenal Artery Coils at the Base of Duodenal Ulcer in Case of Recurrent Massive Upper Gastrointestinal Bleed. Cureus 2017;9:e1163. [PMID: 28507835 DOI: 10.7759/cureus.1163] [Reference Citation Analysis]
|
| 277 |
Farah R, Hamza H, Khamisy-Farah R. A link between platelet to lymphocyte ratio and Helicobacter pylori infection. J Clin Lab Anal 2018;32. [PMID: 28374931 DOI: 10.1002/jcla.22222] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 278 |
Abdul Rahim NR, Benson J, Grocke K, Vather D, Zimmerman J, Moody T, Mwanri L. Prevalence of Helicobacter pylori infection in newly arrived refugees attending the Migrant Health Service, South Australia. Helicobacter 2017;22. [PMID: 27717096 DOI: 10.1111/hel.12360] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 279 |
Harmati M, Gyukity-Sebestyen E, Dobra G, Terhes G, Urban E, Decsi G, Mimica-Dukić N, Lesjak M, Simin N, Pap B, Nemeth IB, Buzas K. Binary mixture of Satureja hortensis and Origanum vulgare subsp. hirtum essential oils: in vivo therapeutic efficiency against Helicobacter pylori infection. Helicobacter 2017;22. [PMID: 27578489 DOI: 10.1111/hel.12350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 280 |
Pradhan F, Hughes D, Narasimhan RA. Management of Upper Gastrointestinal Bleeding. Hospital Medicine Clinics 2017;6:261-82. [DOI: 10.1016/j.ehmc.2016.11.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 281 |
Kamboj AK, Cotter TG, Oxentenko AS. Helicobacter pylori. Mayo Clinic Proceedings 2017;92:599-604. [DOI: 10.1016/j.mayocp.2016.11.017] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 282 |
Marin AC, Nyssen OP, Mcnicholl AG, Gisbert JP. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs 2017;77:765-76. [DOI: 10.1007/s40265-017-0730-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 283 |
Kurt O, Ozturk K, Altun B. Association between Helicobacter pylori and Gastric Cancers. Gut Liver 2017;11:312-3. [PMID: 26780091 DOI: 10.5009/gnl15316] [Reference Citation Analysis]
|
| 284 |
Yogo N, Shihadeh K, Young H, Calcaterra SL, Knepper BC, Burman WJ, Mehler PS, Jenkins TC. Intervention to Reduce Broad-Spectrum Antibiotics and Treatment Durations Prescribed at the Time of Hospital Discharge: A Novel Stewardship Approach. Infect Control Hosp Epidemiol 2017;38:534-41. [PMID: 28260538 DOI: 10.1017/ice.2017.10] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 285 |
Park SM, Kim JS, Kim BW, Ji JS, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol 2017;32:589-94. [PMID: 27505301 DOI: 10.1111/jgh.13510] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 286 |
Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, Imai R, Fujisawa T, Mori H, Matsuda Y, Wada S, Horiuchi A, Kiyosawa K. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Can J Gastroenterol Hepatol. 2017;2017:4385161. [PMID: 28349044 DOI: 10.1155/2017/4385161] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 287 |
Tang DM, Kumar S. The Association Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep 2017;19:5. [PMID: 28155087 DOI: 10.1007/s11894-017-0545-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 288 |
Miftahussurur M, Cruz M, Subsomwong P, Jiménez Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg 2017;96:1050-9. [PMID: 28193745 DOI: 10.4269/ajtmh.16-0729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 289 |
Chuah SK, Liang CM, Lee CH, Chiou SS, Chiu YC, Hu ML, Wu KL, Lu LS, Chou YP, Chang KC, Kuo CH, Kuo CM, Hu TH, Tai WC. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication. Medicine (Baltimore) 2016;95:e3586. [PMID: 27175657 DOI: 10.1097/MD.0000000000003586] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 290 |
Abd-Elsalam S, Kobtan A, El-Kalla F, Elkhalawany W, Nawasany SE, Saif SA, Yousef M, Ali LA, Soliman S, Mansour L, Habba E, Soliman H, Rizk F, Shehata MA. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore) 2016;95:e3879. [PMID: 27310977 DOI: 10.1097/MD.0000000000003879] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 291 |
Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Med Clin North Am 2016;100:827-50. [PMID: 27235617 DOI: 10.1016/j.mcna.2016.03.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 292 |
Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23:e880-e893. [PMID: 25569598 DOI: 10.1097/mjt.0000000000000191] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 293 |
Worden JC, Hanna KS. Optimizing proton pump inhibitor therapy for treatment of nonvariceal upper gastrointestinal bleeding. American Journal of Health-System Pharmacy 2017;74:109-16. [DOI: 10.2146/ajhp151032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 294 |
Martins GM, Sanches BS, Moretzsohn LD, Lima KS, Cota BD, Coelho LG. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in an urban brazilian population. Arq Gastroenterol. 2016;53:113-117. [PMID: 27305419 DOI: 10.1590/s0004-28032016000200012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 295 |
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017;112:212-39. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 744] [Cited by in F6Publishing: 743] [Article Influence: 124.0] [Reference Citation Analysis]
|
| 296 |
Chung KT, Shelat VG. Perforated peptic ulcer - an update. World J Gastrointest Surg 2017; 9(1): 1-12 [PMID: 28138363 DOI: 10.4240/wjgs.v9.i1.1] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 117] [Article Influence: 18.2] [Reference Citation Analysis]
|
| 297 |
Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 298 |
Kim SB, Lee SH, Kim KO, Jang BI, Kim TN. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection]. Korean J Gastroenterol 2015;66:261-7. [PMID: 26586348 DOI: 10.4166/kjg.2015.66.5.261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 299 |
Hernandez SE, Etchill EW, Zuckerbraun BS. The Immunosuppressed Patient. Complications in Acute Care Surgery 2017. [DOI: 10.1007/978-3-319-42376-0_22] [Reference Citation Analysis]
|
| 300 |
Mosińska P, Sałaga M. Diagnostic Criteria in Peptic Ulcer Disease. Introduction to Gastrointestinal Diseases Vol. 2 2017. [DOI: 10.1007/978-3-319-59885-7_4] [Reference Citation Analysis]
|
| 301 |
Park CH. The first-line regimens of Helicobacter pylori eradication in Korea. Hanyang Med Rev 2017;37:2. [DOI: 10.7599/hmr.2017.37.1.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 302 |
Wasilewski A, Mosińska P. Patient’s Guide: Helicobacter pylori in Peptic Ulcer Disease. Introduction to Gastrointestinal Diseases Vol. 2 2017. [DOI: 10.1007/978-3-319-59885-7_8] [Reference Citation Analysis]
|
| 303 |
Darbari A, Sehgal S, Rawal N, Imhoff R. Pharmacological Reflux Therapies. Esophageal and Gastric Disorders in Infancy and Childhood 2017. [DOI: 10.1007/978-3-642-11202-7_85] [Reference Citation Analysis]
|
| 304 |
Corey BL, Grams JM, Christein JD, Vickers SM. Benign Disease of Stomach and Duodenum. Principles and Practice of Geriatric Surgery 2017. [DOI: 10.1007/978-3-319-20317-1_66-1] [Reference Citation Analysis]
|
| 305 |
Piper MS, Hall KE. Gastroenterology. Geriatrics for Specialists 2017. [DOI: 10.1007/978-3-319-31831-8_23] [Reference Citation Analysis]
|
| 306 |
Qi Q, Guo C, Ji R, Li Z, Zuo X, Li Y. Diagnostic Performance of Magnifying Endoscopy for Helicobacter pylori Infection: A Meta-Analysis. PLoS One. 2016;11:e0168201. [PMID: 27992489 DOI: 10.1371/journal.pone.0168201] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 307 |
Lash RH, Genta RM. Routine Anti-Helicobacter Immunohistochemical Staining is Significantly Superior to Reflex Staining Protocols for the Detection of Helicobacter in Gastric Biopsy Specimens. Helicobacter 2016;21:581-5. [PMID: 27172813 DOI: 10.1111/hel.12315] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 308 |
Liou JM, Wu MS, Lin JT. Treatment of Helicobacter pylori infection: Where are we now? J Gastroenterol Hepatol 2016;31:1918-26. [PMID: 27088632 DOI: 10.1111/jgh.13418] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 309 |
Tabiri S, Akanbong P, Abubakari BB. Assessment of the environmental risk factors for a gastric ulcer in northern Ghana. Pan Afr Med J 2016;25:160. [PMID: 28292122 DOI: 10.11604/pamj.2016.25.160.8531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 310 |
Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 192] [Cited by in F6Publishing: 204] [Article Influence: 27.4] [Reference Citation Analysis]
|
| 311 |
Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016;16:256. [PMID: 27809767 DOI: 10.1186/s12866-016-0873-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 312 |
Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Liou TC, Chang WH, Hsu YC, Tseng CH, Chang CC, Bair MJ, Liu TY, Hsieh CF, Tsao FY, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut 2016;65:1784-92. [PMID: 26338825 DOI: 10.1136/gutjnl-2015-310142] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 313 |
Campbell R, Kilty SJ, Hutton B, Bonaparte JP. The Role of Helicobacter pylori in Laryngopharyngeal Reflux. Otolaryngol Head Neck Surg. 2017;156:255-262. [PMID: 27803078 DOI: 10.1177/0194599816676052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 314 |
Zhang Y, Xiu M, Jiang J, He J, Li D, Liang S, Chen Q. Novokinin inhibits gastric acid secretion and protects against alcohol-induced gastric injury in rats. Alcohol 2016;56:1-8. [PMID: 27814789 DOI: 10.1016/j.alcohol.2016.08.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 315 |
Zhu TT, Wang L, Wang HL, He Y, Ma X, Fan JM. Helicobacter pylori participates in the pathogenesis of IgA nephropathy. Ren Fail 2016;38:1398-404. [PMID: 27764998 DOI: 10.1080/0886022X.2016.1216713] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 316 |
Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016;388:2355-2365. [PMID: 27769562 DOI: 10.1016/s0140-6736(16)31409-x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 317 |
Lü M, Yu S, Deng J, Yan Q, Yang C, Xia G, Zhou X. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One 2016;11:e0163743. [PMID: 27723762 DOI: 10.1371/journal.pone.0163743] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 318 |
Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, Wu JY, Kuo CH, Huang YK, Wu DC. Diagnosis of Helicobacter pylori infection: Current options and developments. World J Gastroenterol. 2015;21:11221-11235. [PMID: 26523098 DOI: 10.3748/wjg.v21.i40.11221.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 319 |
Zheng HM, Choi MJ, Kim JM, Lee KW, Park YH, Lee DH. In vitro and In vivo Anti-Helicobacter pylori Activities of Centella asiatica Leaf Extract. Prev Nutr Food Sci 2016;21:197-201. [PMID: 27752495 DOI: 10.3746/pnf.2016.21.3.197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 320 |
Abuhammour A, Dajani A, Nounou M, Zakaria M. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. Arab J Gastroenterol 2016;17:131-6. [PMID: 27665525 DOI: 10.1016/j.ajg.2016.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 321 |
Semrau A, Gerold S, Frick JS, Iglauer F. Non-invasive detection and successful treatment of a Helicobacter pylori infection in a captive rhesus macaque. Lab Anim 2017;51:208-11. [PMID: 27609810 DOI: 10.1177/0023677216669179] [Reference Citation Analysis]
|
| 322 |
Sanches BS, Martins GM, Lima K, Cota B, Moretzsohn LD, Ribeiro LT, Breyer HP, Maguilnik I, Maia AB, Rezende-Filho J, Meira AC, Pinto H, Alves E, Mascarenhas R, Passos R, de Souza JD, Trindade OR, Coelho LG. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. World J Gastroenterol 2016; 22(33): 7587-7594 [PMID: 27672279 DOI: 10.3748/wjg.v22.i33.7587] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 323 |
Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016;65:1439-46. [PMID: 26935876 DOI: 10.1136/gutjnl-2015-311304] [Cited by in Crossref: 214] [Cited by in F6Publishing: 189] [Article Influence: 30.6] [Reference Citation Analysis]
|
| 324 |
Yamamoto T, Matsui H, Yamaji K, Takahashi T, Øverby A, Nakamura M, Matsumoto A, Nonaka K, Sunazuka T, Ōmura S, Nakano H. Narrow-spectrum inhibitors targeting an alternative menaquinone biosynthetic pathway of Helicobacter pylori. Journal of Infection and Chemotherapy 2016;22:587-92. [DOI: 10.1016/j.jiac.2016.05.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 325 |
Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 2016;44:427-37. [PMID: 27363687 DOI: 10.1111/apt.13712] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 326 |
Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, Dogantzis P, Vlachou E, Kalantzis C, Tsibouris P, Alexandrakis G. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol 2016;51:145-51. [PMID: 26435055 DOI: 10.3109/00365521.2015.1079646] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 327 |
Dohi O, Yagi N, Onozawa Y, Kimura-Tsuchiya R, Majima A, Kitaichi T, Horii Y, Suzuki K, Tomie A, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Itoh Y. Linked color imaging improves endoscopic diagnosis of active Helicobacter pylori infection. Endosc Int Open. 2016;4:E800-E805. [PMID: 27556101 DOI: 10.1055/s-0042-109049] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 328 |
Siddiqui I, Ahmed S, Abid S. Update on diagnostic value of breath test in gastrointestinal and liver diseases. World J Gastrointest Pathophysiol 2016; 7(3): 256-265 [PMID: 27574563 DOI: 10.4291/wjgp.v7.i3.256] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 329 |
Yang Y, Xiong W, Wang S, Xu J, McNutt MA, Zhang L. Factors Associated With Detection of Helicobacter pylori in Gastric Biopsies: A Case-Control Study of 396 Biopsies. Appl Immunohistochem Mol Morphol 2018;26:345-50. [PMID: 27490761 DOI: 10.1097/PAI.0000000000000421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 330 |
Rogers BB, Gold BD. Helicobacter pylori Gastritis: Susceptible to Further Testing? Dig Dis Sci 2016;61:2156-9. [PMID: 27234271 DOI: 10.1007/s10620-016-4200-8] [Reference Citation Analysis]
|
| 331 |
Park JY, Dunbar KB, Mitui M, Arnold CA, Lam-Himlin DM, Valasek MA, Thung I, Okwara C, Coss E, Cryer B, Doern CD. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. Dig Dis Sci 2016;61:2373-80. [PMID: 26923948 DOI: 10.1007/s10620-016-4091-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 332 |
Hu Q, Zhang Y, Zhang X, Fu K. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management. Biomark Res. 2016;4:15. [PMID: 27468353 DOI: 10.1186/s40364-016-0068-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 333 |
Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, Wu O. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol. 2016;16:80. [PMID: 27460211 DOI: 10.1186/s12876-016-0491-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 334 |
Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One 2016;11:e0160007. [PMID: 27454429 DOI: 10.1371/journal.pone.0160007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 335 |
Upala S, Jaruvongvanich V, Riangwiwat T, Jaruvongvanich S, Sanguankeo A. Association between Helicobacter pylori infection and metabolic syndrome: a systematic review and meta-analysis. J Dig Dis 2016;17:433-40. [PMID: 27273478 DOI: 10.1111/1751-2980.12367] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 336 |
Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol 2016;111:949-56. [PMID: 27185079 DOI: 10.1038/ajg.2016.182] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 337 |
Yepes Barreto IDJ, Osorio Marín C, Múnera Contreras MN. Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori. Rev Cienc Biomed 2016;7:258-264. [DOI: 10.32997/rcb-2016-2854] [Reference Citation Analysis]
|
| 338 |
Brownlee AR, Bromberg E, Roslin MS. Outcomes in Patients with Helicobacter pylori Undergoing Laparoscopic Sleeve Gastrectomy. Obes Surg 2015;25:2276-9. [PMID: 26001881 DOI: 10.1007/s11695-015-1687-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 339 |
Lin LC, Hsu TH, Huang KW, Tam KW. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. World J Gastroenterol 2016; 22(23): 5445-5453 [PMID: 27340362 DOI: 10.3748/wjg.v22.i23.5445] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 340 |
Hashem-Dabaghian F, Agah S, Taghavi-Shirazi M, Ghobadi A. Combination of Nigella sativa and Honey in Eradication of Gastric Helicobacter pylori Infection. Iran Red Crescent Med J 2016;18:e23771. [PMID: 28191328 DOI: 10.5812/ircmj.23771] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 341 |
Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient Prefer Adherence 2016;10:1025-35. [PMID: 27354772 DOI: 10.2147/PPA.S102760] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 342 |
Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2016;28:676-83. [PMID: 26862930 DOI: 10.1097/MEG.0000000000000590] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 343 |
Agréus L, Talley NJ, Jones M. Value of the "Test & Treat" Strategy for Uninvestigated Dyspepsia at Low Prevalence Rates of Helicobacter pylori in the Population. Helicobacter 2016;21:186-91. [PMID: 26347458 DOI: 10.1111/hel.12267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 344 |
Agrawal S. Gastric Intestinal Metaplasia and Helicobacter Pylori Testing. GHOA 2016;4. [DOI: 10.15406/ghoa.2016.04.00121] [Reference Citation Analysis]
|
| 345 |
Koff JL, Chihara D, Phan A, Nastoupil LJ, Williams JN, Flowers CR. To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. Curr Hematol Malig Rep 2015;10:244-55. [PMID: 26104907 DOI: 10.1007/s11899-015-0267-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 346 |
Kim BJ, Kim HS, Song HJ, Chung IK, Kim GH, Kim BW, Shim KN, Jeon SW, Jung YJ, Yang CH, Kim JH, Kim TH, Kim SG, Shin WG, Kim SM, Han SW, Lee JH, Kim KH, Park SK, Park BJ, Lee J, Kim JG; Korean College of Helicobacter and Upper Gastrointestinal Research. Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis. J Korean Med Sci 2016;31:1246-53. [PMID: 27478335 DOI: 10.3346/jkms.2016.31.8.1246] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 347 |
Shahrashoob M, Mohsenifar A, Tabatabaei M, Rahmani-cherati T, Mobaraki M, Mota A, Shojaei TR. Detection of Helicobacter Pylori Genome with an Optical Biosensor Based on Hybridization of Urease Gene with a Gold Nanoparticles-Labeled Probe. J Appl Spectrosc 2016;83:322-9. [DOI: 10.1007/s10812-016-0290-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 348 |
Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: When and How to Test for Helicobacter pylori Infection. Gastroenterol Res Pract 2016;2016:8463614. [PMID: 27239194 DOI: 10.1155/2016/8463614] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 349 |
Demirci H, Ozturk K, Kurt O. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication. World J Gastroenterol 2016; 22(15): 4071-4072 [PMID: 27099453 DOI: 10.3748/wjg.v22.i15.4071] [Reference Citation Analysis]
|
| 350 |
Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, Le TK, Quek K, Pham VH. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000Res 2016;5:671. [PMID: 27583131 DOI: 10.12688/f1000research.8239.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 351 |
Hsu PI, Kao SS, Wu DC, Chen WC, Peng NJ, Yu HC, Wang HM, Lai KH, Cheng JS, Chen A. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. Medicine (Baltimore). 2015;94:e2104. [PMID: 26632893 DOI: 10.1097/md.0000000000002104] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 352 |
Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P, Das R. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. J Glob Antimicrob Resist. 2016;6:39-43. [PMID: 27530837 DOI: 10.1016/j.jgar.2016.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 353 |
Kiss S, Zsikla V, Frank A, Willi N, Cathomas G. Helicobacter-negative gastritis: polymerase chain reaction for Helicobacter DNA is a valuable tool to elucidate the diagnosis. Aliment Pharmacol Ther 2016;43:924-32. [PMID: 26890160 DOI: 10.1111/apt.13564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 354 |
Hu B, Zhao F, Wang S, Olszewski MA, Bian H, Wu Y, Kong M, Xu L, Miao Y, Fang Y, Yang C, Zhao H, Zhang Y. A high-throughput multiplex genetic detection system for Helicobacter pylori identification, virulence and resistance analysis. Future Microbiol 2016;11:1261-78. [PMID: 27023051 DOI: 10.2217/fmb-2016-0023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 355 |
Shaikh T, Fallone CA. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice. Can J Gastroenterol Hepatol 2016;2016:7321574. [PMID: 27446864 DOI: 10.1155/2016/7321574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 356 |
Al-Badriyeh D, Alabbadi I, Fahey M, Al-Khal A, Zaidan M. Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar. Clin Ther 2016;38:1158-73. [PMID: 27021610 DOI: 10.1016/j.clinthera.2016.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 357 |
Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut Liver. 2015;9:478-485. [PMID: 25071068 DOI: 10.5009/gnl14020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 358 |
Khalil MA, El-Sheekh MM, El-Adawi HI, El-Deeb NM, Hussein MZ. Efficacy of microencapsulated lactic acid bacteria in Helicobater pylori eradication therapy. J Res Med Sci. 2015;20:950-957. [PMID: 26929759 DOI: 10.4103/1735-1995.172782] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 359 |
Liou JM, Bair MJ, Chen CC, Lee YC, Chen MJ, Chen CC, Tseng CH, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Chang WH, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hung HW, Lin JT, Chang CY, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial. Am J Gastroenterol 2016;111:381-7. [PMID: 26832653 DOI: 10.1038/ajg.2015.439] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 360 |
Li J, Yang W, Cui R, Wang D, Chang Y, Gu W, Yin W, Bai X, Chen K, Xia L, Geng H, Xing G. Metabolizer in vivo of fullerenes and metallofullerenes by positron emission tomography. Nanotechnology 2016;27:155101. [DOI: 10.1088/0957-4484/27/15/155101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 361 |
Sung JK. Diagnosis and management of gastric dysplasia. Korean J Intern Med 2016;31:201-9. [PMID: 26932397 DOI: 10.3904/kjim.2016.021] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 362 |
Cao D, Jiang J, You L, Jia Z, Tsukamoto T, Cai H, Wang S, Hou Z, Suo YE, Cao X. The protective effects of 18β-glycyrrhetinic acid on Helicobacter pylori-infected gastric mucosa in Mongolian Gerbils. Biomed Res Int. 2016;2016:4943793. [PMID: 27006947 DOI: 10.1155/2016/4943793] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 363 |
Jonaitis L, Kiudelis G, Slepavicius P, Kupcinskas L. High rate of Helicobacter pylori reinfection in Lithuanian peptic ulcer patients. World J Gastrointest Pathophysiol 2016; 7(1): 181-185 [PMID: 26909241 DOI: 10.4291/wjgp.v7.i1.181] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 364 |
Zhang F, Bao ZJ, Shi DM, Xiang P, Xiao L, Huang YQ, Zhang GS, Yin SM. Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy. Braz J Med Biol Res 2016;49:e5080. [PMID: 26871968 DOI: 10.1590/1414-431X20155080] [Reference Citation Analysis]
|
| 365 |
Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States. Patient Prefer Adherence 2016;10:45-55. [PMID: 26855566 DOI: 10.2147/PPA.S93320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 366 |
Gurusamy KS, Yaghoobi M, Davidson BR; Cochrane Upper GI and Pancreatic Diseases Group. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 367 |
Yep-gamarra V, Díaz-vélez C, Araujo I, Ginès À, Fernández-esparrach G. Usefulness of systematic chromoendoscopy with a double dye staining technique for the detection of dysplasia in patients with premalignant gastric lesions. Gastroenterología y Hepatología (English Edition) 2016;39:49-54. [DOI: 10.1016/j.gastre.2016.01.005] [Reference Citation Analysis]
|
| 368 |
Liou JM, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, Lin JT, Chen MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2016;43:470-81. [PMID: 26669729 DOI: 10.1111/apt.13495] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 369 |
Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016;43:514-33. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 410] [Cited by in F6Publishing: 381] [Article Influence: 58.6] [Reference Citation Analysis]
|
| 370 |
Calik Z, Karamese M, Acar O, Aksak Karamese S, Dicle Y, Albayrak F, Can S, Guvendi B, Turgut A, Cicek M. Investigation of Helicobacter pylori antigen in stool samples of patients with upper gastrointestinal complaints. Braz J Microbiol. 2016;47:167-171. [PMID: 26887240 DOI: 10.1016/j.bjm.2015.11.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 371 |
Dunn BE, Phadnis SH. Diagnosis of Helicobacter pylori Infection and Assessment of Eradication. Manual of Molecular and Clinical Laboratory Immunology 2016. [DOI: 10.1128/9781555818722.ch45] [Reference Citation Analysis]
|
| 372 |
Wang J, Li WT, Zheng YX, Zhao SS, Li N, Huang Y, Zhou RR, Huang ZB, Fan XG. The Association between Helicobacter pylori Infection and Chronic Hepatitis C: A Meta-Analysis and Trial Sequential Analysis. Gastroenterol Res Pract 2016;2016:8780695. [PMID: 26904112 DOI: 10.1155/2016/8780695] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 373 |
Rasooly MM, Moye NA, Kirshenbaum AS. Helicobacter pylori: A significant and treatable cause of chronic urticaria and angioedema. Nurse Pract. 2015;40:1-6. [PMID: 26383021 DOI: 10.1097/01.NPR.0000471366.32982.f2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 374 |
Miftahussurur M, Yamaoka Y. Diagnostic Methods of Helicobacter pylori Infection for Epidemiological Studies: Critical Importance of Indirect Test Validation. Biomed Res Int 2016;2016:4819423. [PMID: 26904678 DOI: 10.1155/2016/4819423] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 375 |
Satpathi P, Satpathi S, Mohanty S, Mishra SK, Behera PK, Maity AB. Helicobacter pylori infection in dyspeptic patients in an industrial belt of India. Trop Doct 2017;47:2-6. [PMID: 26774110 DOI: 10.1177/0049475515626033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 376 |
Shirin D, Matalon S, Avidan B, Broide E, Shirin H. Real-world Helicobacter pylori diagnosis in patients referred for esophagoduodenoscopy: The gap between guidelines and clinical practice. United European Gastroenterol J 2016;4:762-9. [PMID: 28408993 DOI: 10.1177/2050640615626052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 377 |
Perrone S, D'Elia GM, Annechini G, Pulsoni A. Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy. Mediterr J Hematol Infect Dis 2016;8:e2016006. [PMID: 26740867 DOI: 10.4084/MJHID.2016.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 378 |
Hassounah IA, Shehata NA, Kimsawatde GC, Hudson AG, Sriranganathan N, Joseph EG, Mahajan RL. Designing and testing single tablet for tuberculosis treatment through electrospinning. Fabrication and Self-Assembly of Nanobiomaterials 2016. [DOI: 10.1016/b978-0-323-41533-0.00011-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 379 |
Peek RM Jr. New Biology to New Treatment of Helicobacter pylori-Induced Gastric Cancer. Dig Dis 2016;34:510-6. [PMID: 27332886 DOI: 10.1159/000445231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 380 |
Miftahussurur M, Yamaoka Y. Population-Based Strategies for Helicobacter pylori-Associated Disease Management: Asian Perspective. Helicobacter pylori Research 2016. [DOI: 10.1007/978-4-431-55936-8_23] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 381 |
Yoon H. Sequential Therapy. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_43] [Reference Citation Analysis]
|
| 382 |
Yoon H. Levofloxacin or Rifabutin-Based Triple Therapy. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 383 |
Kim N. Synopsis of H. pylori-Associated Diseases. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_16] [Reference Citation Analysis]
|
| 384 |
Sasaki M. Trends in Global Eradication Rates. Helicobacter pylori 2016. [DOI: 10.1007/978-4-431-55705-0_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 385 |
Mehta H. Abdominal Pain. Clinical Pathways in Emergency Medicine 2016. [DOI: 10.1007/978-81-322-2710-6_26] [Reference Citation Analysis]
|
| 386 |
Molina-infante J, Graham DY. Helicobacter pylori Therapy. Helicobacter pylori Research 2016. [DOI: 10.1007/978-4-431-55936-8_20] [Reference Citation Analysis]
|
| 387 |
Rezaizadeh H, Olson E. Specific GI Microbial Infections. Clinical Gastroenterology 2016. [DOI: 10.1007/978-3-319-33317-5_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 388 |
Burd EM, Hinrichs BH. Gastrointestinal Infections. Molecular Pathology in Clinical Practice 2016. [DOI: 10.1007/978-3-319-19674-9_50] [Reference Citation Analysis]
|
| 389 |
Yoon H. Gastric Cancer. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_53] [Reference Citation Analysis]
|
| 390 |
Choe YH. Extraintestinal Manifestations of H. pylori Infection: H. pylori-Associated Iron-Deficiency Anemia. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_31] [Reference Citation Analysis]
|
| 391 |
Kefeli A, Basyigit S, Yeniova AO, Kefeli TT, Aslan M, Tanas O. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. Bosn J Basic Med Sci 2016;16:52-7. [PMID: 26773183 DOI: 10.17305/bjbms.2016.660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 392 |
Marshall B. A Brief History of the Discovery of Helicobacter pylori. Helicobacter pylori 2016. [DOI: 10.1007/978-4-431-55705-0_1] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 393 |
Huang LC, Azagury DE. His Upper GI Tract. Men's Health 2016. [DOI: 10.1007/978-1-4939-3237-5_5] [Reference Citation Analysis]
|
| 394 |
Molina-infante J. Quadruple Regimens for Helicobacter pylori Infection. Helicobacter pylori 2016. [DOI: 10.1007/978-4-431-55705-0_15] [Reference Citation Analysis]
|
| 395 |
Kim SE. A New Effective Therapy forHelicobacter pyloriEradication Using a Potassium-Competitive Acid Blocker. Korean J Helicobacter Up Gastrointest Res 2016;16:118. [DOI: 10.7704/kjhugr.2016.16.2.118] [Reference Citation Analysis]
|
| 396 |
Syam AF, Miftahussurur M, Uwan WB, Simanjuntak D, Uchida T, Yamaoka Y. Validation of Urine Test for Detection of Helicobacter pylori Infection in Indonesian Population. Biomed Res Int. 2015;2015:152823. [PMID: 26824034 DOI: 10.1155/2015/152823] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 397 |
Arama SS, Tiliscan C, Negoita C, Croitoru A, Arama V, Mihai CM, Pop F, Garg A. Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients. Gastroenterol Res Pract 2016;2016:5061640. [PMID: 26858750 DOI: 10.1155/2016/5061640] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 398 |
Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, Song IS. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol 2015; 21(46): 13124-13131 [PMID: 26673999 DOI: 10.3748/wjg.v21.i46.13124] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 399 |
Yin SM, Zhang F, Shi DM, Xiang P, Xiao L, Huang YQ, Zhang GS, Bao ZJ. Effect of posture on 13C-urea breath test in partial gastrectomy patients. World J Gastroenterol 2015; 21(45): 12888-12895 [PMID: 26668514 DOI: 10.3748/wjg.v21.i45.12888] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 400 |
Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol 2015; 21(45): 12954-12962 [PMID: 26668516 DOI: 10.3748/wjg.v21.i45.12954] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 401 |
Chan CC, Chien NH, Lee CL, Yang YC, Hung CS, Tu TC, Wu CH. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. BMC Gastroenterol 2015;15:170. [PMID: 26635102 DOI: 10.1186/s12876-015-0401-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 402 |
Otto M, Ronellenfitsch U, Tröndle S, Kienle P, Kähler G, Hasenberg T. Is Preoperative Esophagoduodenoscopy Required in all Patients Prior to Bariatric Surgery? Bariatric Surgical Practice and Patient Care 2015;10:160-4. [DOI: 10.1089/bari.2015.0024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 403 |
Abdel-Moein KA, Saeed H, Samir A. Novel detection of Helicobacter pylori in fish: A possible public health concern. Acta Trop 2015;152:141-4. [PMID: 26364719 DOI: 10.1016/j.actatropica.2015.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 404 |
Ingram RJ, Ragunath K, Atherton JC. Peptic Ulcer Disease. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch56] [Reference Citation Analysis]
|
| 405 |
Hillard JR, Kashup S. Managing Helicobacter pylori in college health, with special considerations for international students. J Am Coll Health 2016;64:404-8. [PMID: 26595094 DOI: 10.1080/07448481.2015.1085053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 406 |
Üçüncü MZ, Kabul Gürbulak E, Gürbulak B, Savaş OA, Özütürk B, Dural AC, Haşlak A. Relationship between atrophic gastritis, gastric intestinal metaplasia and Helicobacter pylori on endoscopic screening of upper gastrointestinal tract and a brief review of the literature: Endoscopic screening of upper gastrointestinal tract for gastric mucosal disorders. Eur Surg 2016;48:99-104. [DOI: 10.1007/s10353-015-0378-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 407 |
Altun B, Ozturk K. Efficiency of Moxifloxacin in the Treatment of Helicobacter pylori Infection. Gut Liver 2015;9:809-10. [PMID: 26087796 DOI: 10.5009/gnl14469] [Reference Citation Analysis]
|
| 408 |
Syam AF, Miftahussurur M, Makmun D, Nusi IA, Zain LH, Zulkhairi , Akil F, Uswan WB, Simanjuntak D, Uchida T. Risk Factors and Prevalence of Helicobacter pylori in Five Largest Islands of Indonesia: A Preliminary Study. PLoS One. 2015;10:e0140186. [PMID: 26599790 DOI: 10.1371/journal.pone.0140186] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 409 |
Chien LN, Huang YJ, Shao YH, Chang CJ, Chuang MT, Chiou HY, Yen Y. Proton pump inhibitors and risk of periampullary cancers--A nested case-control study. Int J Cancer. 2016;138:1401-1409. [PMID: 26488896 DOI: 10.1002/ijc.29896] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 410 |
Sokic-Milutinovic A, Alempijevic T, Milosavljevic T. Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol 2015; 21(41): 11654-11672 [PMID: 26556993 DOI: 10.3748/wjg.v21.i41.11654] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 411 |
Yep-Gamarra V, Díaz-Vélez C, Araujo I, Ginès À, Fernández-Esparrach G. [Usefulness of systematic chromoendoscopy with a double dye staining technique for the detection of dysplasia in patients with premalignant gastric lesions]. Gastroenterol Hepatol 2016;39:49-54. [PMID: 26548735 DOI: 10.1016/j.gastrohep.2015.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 412 |
Yazdanbod A, Salimian S, Habibzadeh S, Hooshyar A, Maleki N, Norouzvand M. Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial. Arch Med Sci. 2015;11:964-969. [PMID: 26528337 DOI: 10.5114/aoms.2015.54851] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
|
| 413 |
Haider RB, Brennan DE, Omorogbe J, Holleran G, Hall B, O'Morain C, Breslin N, O'Connor HJ, Smith SM, McNamara D. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. Eur J Gastroenterol Hepatol 2015;27:1265-9. [PMID: 26287955 DOI: 10.1097/MEG.0000000000000457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 414 |
Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, Wu JY, Kuo CH, Huang YK, Wu DC. Diagnosis of Helicobacter pylori infection: Current options and developments. World J Gastroenterol 2015; 21(40): 11221-11235 [PMID: 26523098 DOI: 10.3748/wjg.v21.i40.11221] [Cited by in CrossRef: 185] [Cited by in F6Publishing: 205] [Article Influence: 23.1] [Reference Citation Analysis]
|
| 415 |
Wong A, Ching SS, Long AS. The use of a second biopsy from the gastric body for the detection of Helicobacter pylori using rapid urease test. Singapore Med J. 2014;55:644-647. [PMID: 25630318 DOI: 10.11622/smedj.2014178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 416 |
Wang CH, Liao ST, Yang J, Li CX, Yang YY, Han R, Chen DF, Lan CH. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. World J Gastroenterol 2015; 21(39): 11179-11184 [PMID: 26494972 DOI: 10.3748/wjg.v21.i39.11179] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 417 |
Senatore FJ, Wilmot J, Birk JW. Helicobacter pylori treatment: Still a work in progress. Postgrad Med. 2016;128:152-157. [PMID: 26490697 DOI: 10.1080/00325481.2016.1103194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 418 |
Weiner N, Shaoul R. Impact of Age, Gender, and Addition of Probiotics on Treatment Success for Helicobacter pylori in Children. Glob Pediatr Health 2015;2:2333794X15607798. [PMID: 27335981 DOI: 10.1177/2333794X15607798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 419 |
Oh JK, Weiderpass E. Infection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014;80:384-392. [PMID: 25512154 DOI: 10.1016/j.aogh.2014.09.013] [Cited by in Crossref: 108] [Cited by in F6Publishing: 117] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 420 |
Allen JI, Katzka D, Robert M, Leontiadis GI. American Gastroenterological Association Institute Technical Review on the Role of Upper Gastrointestinal Biopsy to Evaluate Dyspepsia in the Adult Patient in the Absence of Visible Mucosal Lesions. Gastroenterology 2015;149:1088-118. [PMID: 26278504 DOI: 10.1053/j.gastro.2015.07.040] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 421 |
Lamouliatte H, Zerbib F, Fotsing G, Chabrun E, Mégraud F, Cayla R, Cazorla S, Talbi P. La quadrithérapie bismuthée est supérieure au traitement séquentiel pour l’éradication de Helicobacter pylori : résultats d’une étude comparative en routine. Acta Endosc 2015;45:198-202. [DOI: 10.1007/s10190-015-0514-1] [Reference Citation Analysis]
|
| 422 |
Rakici H, Ayaz T, Akdogan RA, Bedir R. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. Digestion 2014;90:261-4. [PMID: 25547786 DOI: 10.1159/000369788] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 423 |
Zhang XH, He Y, Feng R, Xu LP, Jiang Q, Jiang H, Lu J, Fu HX, Liu H, Wang JW, Wang QM, Feng FE, Zhu XL, Xu LL, Xie YD, Ma H, Wang H, Liu KY, Huang XJ. Helicobacter pylori infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. Platelets 2016;27:223-9. [PMID: 26338255 DOI: 10.3109/09537104.2015.1077946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 424 |
Sgourakis G, Pindireki A, Kouloura A, Sourtse G, Ganis V, Peristeraki S, Karkoulias K, Georgopoulos S, Karaliotas C, Lanitis S. Eradication rates for Helicobacter pylori infection a systematic evidence - based review. Hellenic J Surg 2015;87:377-386. [DOI: 10.1007/s13126-015-0244-z] [Reference Citation Analysis]
|
| 425 |
Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol 2015;13:1616-24. [PMID: 25681693 DOI: 10.1016/j.cgh.2015.02.005] [Cited by in Crossref: 110] [Cited by in F6Publishing: 109] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 426 |
Sapmaz F, Kalkan IH, Suslu I, Demirci H, Atasoy P, Guliter S. Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus. J Dig Dis 2015;16:531-6. [PMID: 26147605 DOI: 10.1111/1751-2980.12272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 427 |
Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2015;30:1338-45. [PMID: 25867718 DOI: 10.1111/jgh.12984] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 428 |
Wong CW, Chung PH, Tam PK, Wong KK. Laparoscopic versus open operation for perforated peptic ulcer in pediatric patients: A 10-year experience. J Pediatr Surg 2015;50:2038-40. [PMID: 26386878 DOI: 10.1016/j.jpedsurg.2015.08.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 429 |
Srinarong C, Siramolpiwat S, Wongcha-um A, Mahachai V, Vilaichone RK. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. Asian Pac J Cancer Prev 2014;15:9909-13. [PMID: 25520127 DOI: 10.7314/apjcp.2014.15.22.9909] [Cited by in Crossref: 25] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 430 |
Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19:1637-1650. [PMID: 26245678 DOI: 10.1517/14728222.2015.1073261] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 431 |
Choi JM, Kim SG. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection: Korean and Overseas Guidelines. Korean J Med 2015;89:157-68. [DOI: 10.3904/kjm.2015.89.2.157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 432 |
Sung JK. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection. Korean J Med 2015;89:149-56. [DOI: 10.3904/kjm.2015.89.2.149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 433 |
Meltzer AC, Winter LE, Kulie P, Benedict C, Lim K, Ishmukhamedov O, Mccarthy ML. Treating Gastritis, Peptic Ulcer Disease, and Dyspepsia in the Emergency Department: The Feasibility and Patient-Reported Outcomes of Testing and Treating for Helicobacter pylori Infection. Annals of Emergency Medicine 2015;66:131-9. [DOI: 10.1016/j.annemergmed.2015.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 434 |
Dede F, Civen H, Dane F, Aliustaoglu M, Turhal S, Turoglu HT, Inanir S. Carbon-14 urea breath test: does it work in patients with partial gastric resection? Ann Nucl Med 2015;29:786-91. [DOI: 10.1007/s12149-015-1005-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 435 |
Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis. Pharmacotherapy. 2015;35:719-730. [PMID: 26173786 DOI: 10.1002/phar.1614] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 436 |
Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication. World J Gastroenterol 2015; 21(26): 8132-8139 [PMID: 26185386 DOI: 10.3748/wjg.v21.i26.8132] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 437 |
Harb AH, Chalhoub JM, Abou Mrad R, Sharara AI. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2015;42:131-41. [PMID: 26011564 DOI: 10.1111/apt.13259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 438 |
Glickman JN, Noffsinger A, Nevin DT, Ray M, Lash RH, Genta RM. Helicobacter infections with rare bacteria or minimal gastritis: Expecting the unexpected. Dig Liver Dis 2015;47:549-55. [PMID: 26003395 DOI: 10.1016/j.dld.2015.04.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 439 |
Patel KA, Howden CW. Update on the Diagnosis and Management of Helicobacter pylori Infection in Adults. J Clin Gastroenterol 2015;49:461-7. [PMID: 25811119 DOI: 10.1097/MCG.0000000000000318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 440 |
Wong SH, Sung JJ. Management of Patients with Rebleeding. Gastrointest Endosc Clin N Am 2015;25:569-81. [PMID: 26142039 DOI: 10.1016/j.giec.2015.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 441 |
Moretti E, Figura N, Campagna MS, Gonnelli S, Iacoponi F, Collodel G. Sperm Parameters and Semen Levels of Inflammatory Cytokines in Helicobacter pylori–infected Men. Urology 2015;86:41-7. [DOI: 10.1016/j.urology.2015.02.068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 442 |
Kobayashi T, Glatz M, Horiuchi K, Kawasaki H, Akiyama H, Kaplan DH, Kong HH, Amagai M, Nagao K. Dysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis. Immunity 2015;42:756-66. [PMID: 25902485 DOI: 10.1016/j.immuni.2015.03.014] [Cited by in Crossref: 321] [Cited by in F6Publishing: 262] [Article Influence: 40.1] [Reference Citation Analysis]
|
| 443 |
Minkara MS, Weaver MN, Merz KM. Effect of 10.5 M Aqueous Urea on Helicobacter pylori Urease: A Molecular Dynamics Study. Biochemistry 2015;54:4121-30. [DOI: 10.1021/acs.biochem.5b00078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 444 |
McMahon BJ, Bruce MG, Koch A, Goodman KJ, Tsukanov V, Mulvad G, Borresen ML, Sacco F, Barrett D, Westby S, Parkinson AJ. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary. Epidemiol Infect 2016;144:225-33. [PMID: 26094936 DOI: 10.1017/S0950268815001181] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 445 |
Salimi A, Eybagi S, Seydi E, Naserzadeh P, Kazerouni NP, Pourahmad J. Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. Xenobiotica 2016;46:82-93. [PMID: 26068526 DOI: 10.3109/00498254.2015.1046975] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 446 |
Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol 2015; 21(21): 6698-6705 [PMID: 26074708 DOI: 10.3748/wjg.v21.i21.6698] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 447 |
Liu X, Wang H, Lv Z, Wang Y, Wang B, Xie Y, Zhou X, Lv N. Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2015;2015:415648. [PMID: 26106411 DOI: 10.1155/2015/415648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 448 |
Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication. World J Gastroenterol 2015; 21(18): 5568-5574 [PMID: 25987781 DOI: 10.3748/wjg.v21.i18.5568] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 449 |
Marsicano E, Vuong GM, Prather CM. Gastrointestinal causes of abdominal pain. Obstet Gynecol Clin North Am 2014;41:465-89. [PMID: 25155126 DOI: 10.1016/j.ogc.2014.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 450 |
Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015;13:895-905.e5. [PMID: 25460556 DOI: 10.1016/j.cgh.2014.10.036] [Cited by in Crossref: 107] [Cited by in F6Publishing: 80] [Article Influence: 13.4] [Reference Citation Analysis]
|
| 451 |
Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. World J Gastroenterol 2015; 21(16): 5032-5038 [PMID: 25945019 DOI: 10.3748/wjg.v21.i16.5032] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 452 |
Wang H, Ran J, Jiang T. Urea. Subcell Biochem 2014;73:7-29. [PMID: 25298336 DOI: 10.1007/978-94-017-9343-8_2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 453 |
Zhang S, Lee DS, Morrissey R, Aponte-Pieras JR, Rogers AB, Moss SF. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Lett. 2015;359:345-351. [PMID: 25853150 DOI: 10.1016/j.canlet.2015.01.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 454 |
Rizwan M, Fatima N, Alvi A. Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: scenario from Saudi Arabia. Saudi J Gastroenterol 2014;20:212-8. [PMID: 25038206 DOI: 10.4103/1319-3767.136935] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 455 |
Khu JV, Lim LL. Helicobacter pylori Eradication Regimens: Is there a Difference? Journal of Pharmacy Practice and Research 2010;40:194-8. [DOI: 10.1002/j.2055-2335.2010.tb00537.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 456 |
Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 457 |
Oppong P, Majumdar D, Atherton J, Bebb J. Helicobacter pylori infection and peptic ulcers. Medicine 2015;43:215-22. [DOI: 10.1016/j.mpmed.2015.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 458 |
Campanati A, Ganzetti G, Martina E, Giannoni M, Gesuita R, Bendia E, Giuliodori K, Sandroni L, Offidani A. Helicobacter pylori infection in psoriasis: results of a clinical study and review of the literature. Int J Dermatol. 2015;54:e109-e114. [PMID: 25808243 DOI: 10.1111/ijd.12798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 459 |
Ogata SK, Gales AC, Kawakami E. Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. Braz J Microbiol 2014;45:1439-48. [PMID: 25763052 DOI: 10.1590/s1517-83822014000400039] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 460 |
Panarelli NC, Ross DS, Bernheim OE, Landzberg ZB, Schuetz AN, Jenkins SG, Landzberg BR, Jessurun J, Yantiss RK. Utility of ancillary stains for Helicobacter pylori in near-normal gastric biopsies. Human Pathology 2015;46:397-403. [DOI: 10.1016/j.humpath.2014.11.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 461 |
Chitapanarux T, Thongsawat S, Pisespongsa P, Leerapun A, Kijdamrongthum P. Effect of Bifidobacterium longum on PPI-based triple therapy for eradication of Helicobacter pylori: A randomized, double-blind placebo-controlled study. Journal of Functional Foods 2015;13:289-94. [DOI: 10.1016/j.jff.2015.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 462 |
Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, Barrio J, Martin-Noguerol E, Gomez-Rodriguez BJ, Botargues-Bote JM, Gomez-Camarero J, Huerta A, Modolell I, Ariño I, Herranz-Bachiller MT, Bermejo F, McNicholl AG, O'Morain C, Gisbert JP; European Registry on H. pylori management (Hp‐EuReg). Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015;41:581-9. [PMID: 25776067 DOI: 10.1111/apt.13069] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 463 |
Anderson S, Christensen S. Hypersensitivity reaction to omeprazole in a patient treated for Helicobacter pylori. Therap Adv Gastroenterol 2015;8:101-4. [PMID: 25729434 DOI: 10.1177/1756283X14564314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 464 |
Yoon H, Lee DH, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Kim JW, Jeong SH, Kim N. Optimal initiation of Helicobacter pylori eradication in patients with peptic ulcer bleeding. World J Gastroenterol 2015; 21(8): 2497-2503 [PMID: 25741160 DOI: 10.3748/wjg.v21.i8.2497] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 465 |
Buzás GM. Fate of meta-analyses: The case of Helicobacter pylori. World J Meta-Anal 2015; 3(1): 20-25 [DOI: 10.13105/wjma.v3.i1.20] [Reference Citation Analysis]
|
| 466 |
Lee JY, Kim N. Diagnosis of Helicobacter pylori by invasive test: histology. Ann Transl Med. 2015;3:10. [PMID: 25705642 DOI: 10.3978/j.issn.2305-5839.2014.11.03] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
|
| 467 |
Masjedizadeh A, Zaeemzadeh N, Mard SA, Vanani GS. Comparing the efficacy of four different protocols for eradicating of Helicobacter pylori infection in Ahvaz, southwest Iran. Prz Gastroenterol. 2015;10:94-99. [PMID: 26557940 DOI: 10.5114/pg.2015.49001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 468 |
Gastrointestinal disorders. The Dentist's Quick Guide to Medical Conditions 2015. [DOI: 10.1002/9781118991473.ch1] [Reference Citation Analysis]
|
| 469 |
Harb AH, El Reda ZD, Sarkis FS, Chaar HF, Sharara AI. Efficacy of reduced-dose regimen of a capsule containing bismuth subcitrate, metronidazole, and tetracycline given with amoxicillin and esomeprazole in the treatment of Helicobacter Pylori infection. United European Gastroenterol J 2015;3:95-6. [PMID: 25653863 DOI: 10.1177/2050640614560787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 470 |
Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, Kim JJ. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. Dig Liver Dis 2015;47:114-8. [PMID: 25467826 DOI: 10.1016/j.dld.2014.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 471 |
Broide E, Shirin H. Evaluation of Exalenz Bioscience's BreathID for Helicobacter pylori detection. Expert Rev Mol Diagn 2015;15:299-312. [PMID: 25634297 DOI: 10.1586/14737159.2015.982537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 472 |
Ferwana M, Abdulmajeed I, Alhajiahmed A, Madani W, Firwana B, Hasan R, Altayar O, Limburg PJ, Murad MH, Knawy B. Accuracy of urea breath test in Helicobacter pylori infection: Meta-analysis. World J Gastroenterol 2015; 21(4): 1305-1314 [PMID: 25632206 DOI: 10.3748/wjg.v21.i4.1305] [Cited by in CrossRef: 116] [Cited by in F6Publishing: 123] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 473 |
Theel ES, Johnson RD, Plumhoff E, Hanson CA. Use of the Optum Labs Data Warehouse to assess test ordering patterns for diagnosis of Helicobacter pylori infection in the United States. J Clin Microbiol 2015;53:1358-60. [PMID: 25609721 DOI: 10.1128/JCM.03464-14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 474 |
Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015;9:707-716. [PMID: 25667617 DOI: 10.3892/etm.2015.2174] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 475 |
dos Santos AA, Carvalho AA. Pharmacological therapy used in the elimination of Helicobacter pylori infection: A review. World J Gastroenterol 2015; 21(1): 139-154 [PMID: 25574087 DOI: 10.3748/wjg.v21.i1.139] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 476 |
Hayashi S, Imamura J, Kimura K, Saeki S, Hishima T. Endoscopic features of lymphoid follicles in Helicobacter pylori-associated chronic gastritis. Dig Endosc 2015;27:53-60. [PMID: 25092073 DOI: 10.1111/den.12335] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 477 |
Chapter 25. Gastrointestinal Diseases. The APhA Complete Review for Pharmacy, 11th Edition 2015. [DOI: 10.21019/9781582122175.ch25] [Reference Citation Analysis]
|
| 478 |
Doffou AS, Attia KA, Bathaix MFY, Bangoura AD, Kissy-anzouan YH, Kouamé HD, Mahassadi KA, N’da KJ, Kouyaté M, Assi C, N’dri-yoman AT. The <i>Helicobacter pylori</i> Eradication Rate in a High Prevalence Area (West Africa): Three Triple Therapy Comparative Study. OJGas 2015;05:200-206. [DOI: 10.4236/ojgas.2015.512030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 479 |
Kelly JJ, Perugini RA, Wang QL, Czerniach DR, Flahive J, Cohen PA. The presence of Helicobacter pylori is not associated with long-term anastomotic complications in gastric bypass patients. Surg Endosc 2015;29:2885-90. [PMID: 25552229 DOI: 10.1007/s00464-014-4022-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 480 |
Posteraro B, Posteraro P, Sanguinetti M. Helicobacter pylori. Molecular Medical Microbiology 2015. [DOI: 10.1016/b978-0-12-397169-2.00068-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 481 |
Günther UL, Chong MG, Volpari T, Koczula KM, Atkins K, Bunce CM, Khanim FL. Metabolic Fluxes in Cancer Metabolism. Tumor Cell Metabolism 2015. [DOI: 10.1007/978-3-7091-1824-5_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 482 |
Bao J, Hu Y, Mei Q, Zhen H, Xu J. Effect of rabeprazole on the transport and distribution of levofloxacin in rat stomachs. Experimental and Therapeutic Medicine 2014;8:1884-1890. [DOI: 10.3892/etm.2014.2031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 483 |
Feng H, Zhou X, Zhang G. Association between cirrhosis and Helicobacter pylori infection: a meta-analysis. Eur J Gastroenterol Hepatol 2014;26:1309-19. [PMID: 25304251 DOI: 10.1097/MEG.0000000000000220] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 484 |
Gómez V, Bhalla R, Heckman MG, Florit PT, Diehl NN, Rawal B, Lynch SA, Loeb DS. Routine Screening Endoscopy before Bariatric Surgery: Is It Necessary? Bariatr Surg Pract Patient Care 2014;9:143-9. [PMID: 25516819 DOI: 10.1089/bari.2014.0024] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 485 |
Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014; 5(4): 392-399 [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 486 |
Wu Y, Zheng Q, Xu Y, Chu W, Cui Y, Wang Y, Zhang H. Insight into the urea binding and K166R mutation stabilizing mechanism of TlpB: Molecular dynamics and principal component analysis study. Chem Res Chin Univ 2014;30:1011-7. [DOI: 10.1007/s40242-014-4135-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 487 |
Sharara AI, Sarkis FS, El-Halabi MM, Malli A, Mansour NM, Azar C, Eloubeidi MA, Mourad FH, Barada K, Sukkarieh I. Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection. United European Gastroenterol J 2014;2:179-88. [PMID: 25360301 DOI: 10.1177/2050640614530919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 488 |
Nagaraja V, Eslick GD. Evidence-based assessment of proton-pump inhibitors in Helicobacter pylori eradication: A systematic review. World J Gastroenterol 2014; 20(40): 14527-14536 [PMID: 25356018 DOI: 10.3748/wjg.v20.i40.14527] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 489 |
Ferreira J, Moss SF. Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection. Curr Treat Options Gastroenterol. 2014;12:373-384. [PMID: 25187235 DOI: 10.1007/s11938-014-0027-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 490 |
Talebi Bezmin Abadi A. Helicobacter pylori: Emergence of a Superbug. Front Med (Lausanne). 2014;1:34. [PMID: 25593908 DOI: 10.3389/fmed.2014.00034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 491 |
Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: Prevention, screening and early diagnosis. World J Gastroenterol 2014; 20(38): 13842-13862 [PMID: 25320521 DOI: 10.3748/wjg.v20.i38.13842] [Cited by in CrossRef: 210] [Cited by in F6Publishing: 230] [Article Influence: 23.3] [Reference Citation Analysis]
|
| 492 |
Momeni A, Rahimian G, Kiasi A, Amiri M, Kheiri S. Effect of licorice versus bismuth on eradication of Helicobacter pylori in patients with peptic ulcer disease. Pharmacognosy Res 2014;6:341-4. [PMID: 25276073 DOI: 10.4103/0974-8490.138289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 493 |
Kim JE, Kim MS, Yoon YS, Chung MJ, Yum DY. Use of selected lactic acid bacteria in the eradication of Helicobacter pylori infection. J Microbiol. 2014;52:955-962. [PMID: 25277407 DOI: 10.1007/s12275-014-4355-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 494 |
Sasaki H, Nagahara A, Hojo M, Asaoka D, Matsumoto K, Osada T, Watanabe S. Ten-year trend of the cumulative Helicobacter pylori eradication rate for the 'Japanese eradication strategy'. Digestion 2013;88:272-8. [PMID: 24356705 DOI: 10.1159/000353313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 495 |
Yang GH, Wu JS, Yang YC, Huang YH, Lu FH, Chang CJ. Gastric Helicobacter pylori infection associated with risk of diabetes mellitus, but not prediabetes. J Gastroenterol Hepatol 2014;29:1794-9. [PMID: 24731067 DOI: 10.1111/jgh.12617] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 496 |
Schulz TR, McBryde ES, Leder K, Biggs BA. Using stool antigen to screen for Helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration. PLoS One 2014;9:e108610. [PMID: 25268809 DOI: 10.1371/journal.pone.0108610] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 497 |
Testerman TL, Morris J. Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol 2014; 20(36): 12781-12808 [PMID: 25278678 DOI: 10.3748/wjg.v20.i36.12781] [Cited by in CrossRef: 178] [Cited by in F6Publishing: 193] [Article Influence: 19.8] [Reference Citation Analysis]
|
| 498 |
Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol 2014; 20(36): 12818-12838 [PMID: 25278680 DOI: 10.3748/wjg.v20.i36.12818] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 499 |
Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34:771-785. [PMID: 25439276 DOI: 10.1016/j.cll.2014.08.008] [Cited by in Crossref: 88] [Cited by in F6Publishing: 97] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 500 |
Lee JY, Kim N. [Future trends of Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol. 2014;63:158-170. [PMID: 24651589 DOI: 10.4166/kjg.2014.63.3.158] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 501 |
Yang GH, Wu JS, Yang YC, Huang YH, Lu FH, Chang CJ. Obesity associated with increased risk of gastric Helicobacter pylori infection in an elderly Chinese population. J Am Geriatr Soc 2014;62:190-2. [PMID: 25180384 DOI: 10.1111/jgs.12618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 502 |
Zhang S, Lee DS, Morrissey R, Aponte-Pieras JR, Rogers AB, Moss SF. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Lett 2014;355:106-12. [PMID: 25218349 DOI: 10.1016/j.canlet.2014.09.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 503 |
Emami MH, Zobeiri M, Rahimi H, Arjomandi F, Daghagzadeh H, Adibi P, Hashemi J. N-acetyl cysteine as an adjunct to standard anti-Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open-label trial. Adv Biomed Res 2014;3:189. [PMID: 25298958 DOI: 10.4103/2277-9175.140403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 504 |
Liu KS, Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, But DY, Wong SY, Leung WK. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014;63:1410-5. [PMID: 24295850 DOI: 10.1136/gutjnl-2013-306120] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 505 |
Rakici H, Akdoğan RA, Bedir R, Copur A, Yilmaz A. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. J Dig Dis 2014;15:508-13. [PMID: 24980811 DOI: 10.1111/1751-2980.12171] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 506 |
Selvaratnam S, Yeoh J, Hsiang J, Patrick AB. A win for the patient: Direct patient notification improves treatment rates of active Helicobacter pylori infection. Australas Med J. 2014;7:350-354. [PMID: 25279011 DOI: 10.4066/amj.2014.2132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 507 |
Chuah SK, Tai WC, Lee CH, Liang CM, Hu TH. Quinolone-containing therapies in the eradication of Helicobacter pylori. Biomed Res Int. 2014;2014:151543. [PMID: 25243116 DOI: 10.1155/2014/151543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 508 |
Rollan A, Arab JP, Camargo MC, Candia R, Harris P, Ferreccio C, Rabkin CS, Gana JC, Cortés P, Herrero R, Durán L, García A, Toledo C, Espino A, Lustig N, Sarfatis A, Figueroa C, Torres J, Riquelme A. Management of Helicobacter pylori infection in Latin America: A Delphi technique-based consensus. World J Gastroenterol 2014; 20(31): 10969-10983 [PMID: 25152601 DOI: 10.3748/wjg.v20.i31.10969] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 509 |
Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20(30): 10338-10347 [PMID: 25132750 DOI: 10.3748/wjg.v20.i30.10338] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 510 |
Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014; 20(29): 9898-9911 [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 72] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 511 |
Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 2014; 20(29): 9912-9921 [PMID: 25110421 DOI: 10.3748/wjg.v20.i29.9912] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 90] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 512 |
Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 2014;19:243-8. [PMID: 25056262 DOI: 10.1111/hel.12146] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 513 |
Smith SM, Haider RB, O'Connor H, McNamara D, O'Morain C. Practical treatment of Helicobacter pylori: a balanced view in changing times. Eur J Gastroenterol Hepatol 2014;26:819-25. [PMID: 24892516 DOI: 10.1097/MEG.0000000000000130] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 514 |
Ji R, Li YQ. Diagnosing Helicobacter pylori infection in vivo by novel endoscopic techniques. World J Gastroenterol 2014; 20(28): 9314-9320 [PMID: 25071325 DOI: 10.3748/wjg.v20.i28.9314] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
|
| 515 |
Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014;58:5936-5942. [PMID: 25070099 DOI: 10.1128/aac.02922-14] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 516 |
Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol 2014; 20(28): 9439-9450 [PMID: 25071338 DOI: 10.3748/wjg.v20.i28.9439] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
|
| 517 |
Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, Hanyu O, Shimano H, Sone H. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014;106:81-87. [PMID: 25110103 DOI: 10.1016/j.diabres.2014.07.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 518 |
Malnick SDH, Melzer E, Attali M, Duek G, Yahav J. Helicobacter pylori: Friend or foe? World J Gastroenterol 2014; 20(27): 8979-8985 [PMID: 25083071 DOI: 10.3748/wjg.v20.i27.8979] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
|
| 519 |
Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. Korean J Gastroenterol. 2013;62:3-26. [PMID: 23954956 DOI: 10.4166/kjg.2013.62.1.3] [Cited by in Crossref: 119] [Cited by in F6Publishing: 128] [Article Influence: 13.2] [Reference Citation Analysis]
|
| 520 |
Cheng NCL, Xu K, Huang Y, Lim CED. Optimum antibiotic doses for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2014. [DOI: 10.1002/14651858.cd011187] [Reference Citation Analysis]
|
| 521 |
Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol 2014;29:1371-86. [PMID: 24758240 DOI: 10.1111/jgh.12607] [Cited by in Crossref: 140] [Cited by in F6Publishing: 134] [Article Influence: 15.6] [Reference Citation Analysis]
|
| 522 |
Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2014;40:171-7. [PMID: 24863854 DOI: 10.1111/apt.12808] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 523 |
Huang TC, Lee CL. Diagnosis, treatment, and outcome in patients with bleeding peptic ulcers and Helicobacter pylori infections. Biomed Res Int. 2014;2014:658108. [PMID: 25101293 DOI: 10.1155/2014/658108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 524 |
Iwamoto A, Tanahashi T, Okada R, Yoshida Y, Kikuchi K, Keida Y, Murakami Y, Yang L, Yamamoto K, Nishiumi S, Yoshida M, Azuma T. Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes. Gut Pathog. 2014;6:27. [PMID: 24995043 DOI: 10.1186/1757-4749-6-27] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 525 |
Wu MC, Huang CY, Kuo FC, Hsu WH, Wang SS, Shih HY, Liu CJ, Chen YH, Wu DC, Huang YL, Lu CY. The effect of Helicobacter pylori eradication on the levels of essential trace elements. Biomed Res Int 2014;2014:513725. [PMID: 25548772 DOI: 10.1155/2014/513725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 526 |
Chung JW, Ha M, Yun SC, Kim JH, Lee JJ, Kim YJ, Kim KO, Kwon KA, Park DK, Lee DH. Meta-analysis: Sequential therapy is superior to conventional therapy for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2013;62:267-271. [PMID: 24262591 DOI: 10.4166/kjg.2013.62.5.267] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 527 |
Hinojosa WI, Quiróz MA, Álvarez IR, Castañeda PE, Villarreal ML, Taketa AC. Anti-Helicobacter pylori, gastroprotective, anti-inflammatory, and cytotoxic activities of methanolic extracts of five different populations of Hippocratea celastroides collected in Mexico. J Ethnopharmacol 2014;155:1156-63. [PMID: 24971795 DOI: 10.1016/j.jep.2014.06.044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 528 |
Kang KK, Lee DH, Oh DH, Yoon H, Shin CM, Park YS, Kim N, Jung HC. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014; 20(22): 6932-6938 [PMID: 24944485 DOI: 10.3748/wjg.v20.i22.6932] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 529 |
Freedberg DE, Abrams JA, Wang TC. Prevention of gastric cancer with antibiotics: can it be done without eradicating Helicobacter pylori? J Natl Cancer Inst 2014;106:dju148. [PMID: 24925352 DOI: 10.1093/jnci/dju148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 530 |
Chen MC, Lei WY, Lin JS, Yi CH, Wu DC, Hu CT. Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection. Biomed Res Int. 2014;2014:158520. [PMID: 24995271 DOI: 10.1155/2014/158520] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 531 |
van der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. Gut 2014;63:1014-23. [PMID: 24429582 DOI: 10.1136/gutjnl-2013-305418] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 532 |
Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H, Shin CM, Park YS, Lee DH, Jung HC. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 2014;59:1235-43. [PMID: 24599773 DOI: 10.1007/s10620-014-3093-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 533 |
Ali Habib HS, Murad HA, Amir EM, Halawa TF. Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children. Indian J Pharmacol. 2013;45:470-473. [PMID: 24130381 DOI: 10.4103/0253-7613.117757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 534 |
Lu B, Li M. Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol 2014; 20(19): 5660-5665 [PMID: 24914325 DOI: 10.3748/wjg.v20.i19.5660] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 535 |
El-Zimaity H, Serra S, Szentgyorgyi E, Vajpeyi R, Samani A. Gastric biopsies: the gap between evidence-based medicine and daily practice in the management of gastric Helicobacter pylori infection. Can J Gastroenterol 2013;27:e25-30. [PMID: 24106732 DOI: 10.1155/2013/897423] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 536 |
Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014; 20(18): 5252-5262 [PMID: 24833855 DOI: 10.3748/wjg.v20.i18.5252] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 537 |
Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, Miwa H, Lim KJ, Das KM. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol 2014; 20(18): 5461-5473 [PMID: 24833876 DOI: 10.3748/wjg.v20.i18.5461] [Cited by in CrossRef: 145] [Cited by in F6Publishing: 154] [Article Influence: 16.1] [Reference Citation Analysis]
|
| 538 |
Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol 2014; 20(18): 5283-5293 [PMID: 24833858 DOI: 10.3748/wjg.v20.i18.5283] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 111] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 539 |
Alahdab YO, Kalayci C. Helicobacter pylori: Management in 2013. World J Gastroenterol 2014; 20(18): 5302-5307 [PMID: 24833860 DOI: 10.3748/wjg.v20.i18.5302] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 540 |
Horikawa C, Kodama S, Fujihara K, Yachi Y, Tanaka S, Suzuki A, Hanyu O, Shimano H, Sone H. Association of Helicobacter pylori infection with glycemic control in patients with diabetes: a meta-analysis. J Diabetes Res. 2014;2014:250620. [PMID: 24901007 DOI: 10.1155/2014/250620] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 541 |
Park JY, Forman D, Greenberg ER, Herrero R. Helicobacter pylori eradication in the prevention of gastric cancer: are more trials needed? Curr Oncol Rep. 2013;15:517-525. [PMID: 24101366 DOI: 10.1007/s11912-013-0341-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 542 |
Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis. Scand J Gastroenterol 2014;49:528-38. [PMID: 24611790 DOI: 10.3109/00365521.2014.887765] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 543 |
Onyekwere CA, Odiagah JN, Igetei R, Duro Emanuel AO, Ekere F, Smith S. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: Report of an efficacy study. World J Gastroenterol 2014; 20(13): 3615-3619 [PMID: 24707145 DOI: 10.3748/wjg.v20.i13.3615] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 544 |
Zhou L, Zhang J, Chen M, Hou X, Li Z, Song Z, He L, Lin S. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol 2014;109:535-41. [PMID: 24642580 DOI: 10.1038/ajg.2014.26] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 545 |
Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014;109:485-95. [PMID: 24589670 DOI: 10.1038/ajg.2014.24] [Cited by in Crossref: 111] [Cited by in F6Publishing: 119] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 546 |
Talebi Bezmin Abadi A. Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int. 2014;2014:124607. [PMID: 24800203 DOI: 10.1155/2014/124607] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 547 |
Pathak CM, Kaur B, Bhasin DK, Mittal BR, Sharma S, Khanduja KL, Aggarwal L, Rana SS. Comparison of encapsulated versus nonencapsulated (14) C-urea breath test for the detection of Helicobacter pylori infection: a scintigraphy study. Helicobacter 2014;19:116-23. [PMID: 24237714 DOI: 10.1111/hel.12103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 548 |
Kim JJ, Lee JS, Olafsson S, Laine L. Low adherence to Helicobacter pylori testing in hospitalized patients with bleeding peptic ulcer disease. Helicobacter 2014;19:98-104. [PMID: 24617668 DOI: 10.1111/hel.12114] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 549 |
Minkara MS, Ucisik MN, Weaver MN, Merz KM Jr. Molecular Dynamics Study of Helicobacter pylori Urease. J Chem Theory Comput 2014;10:1852-62. [PMID: 24839409 DOI: 10.1021/ct5000023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 550 |
Park JB, Koo JS. Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2014; 20(11): 2751-2759 [PMID: 24659867 DOI: 10.3748/wjg.v20.i11.2751] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 551 |
Binh TT, Shiota S, Suzuki R, Matsuda M, Trang TT, Kwon DH, Iwatani S, Yamaoka Y. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother. 2014;69:1796-1803. [PMID: 24648504 DOI: 10.1093/jac/dku050] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 552 |
Pan-in P, Tachapruetinun A, Chaichanawongsaroj N, Banlunara W, Suksamrarn S, Wanichwecharungruang S. Combating Helicobacter pylori infections with mucoadhesive nanoparticles loaded with Garcinia mangostana extract. Nanomedicine 2014;9:457-68. [DOI: 10.2217/nnm.13.30] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 553 |
Lee H, Jung HK, Huh KC; Functional Dyspepsia Study Group in the Korean Society of Neurogastroenterology and Motility. Current status of functional dyspepsia in Korea. Korean J Intern Med 2014;29:156-65. [PMID: 24648796 DOI: 10.3904/kjim.2014.29.2.156] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 554 |
Dajani AI, Abu Hammour AM, Yang DH, Chung PC, Nounou MA, Yuan KY, Zakaria MA, Schi HS. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? Saudi J Gastroenterol. 2013;19:113-120. [PMID: 23680708 DOI: 10.4103/1319-3767.111953] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 555 |
Fallone CA, Barkun AN, Szilagyi A, Herba KM, Sewitch M, Martel M, Fallone SS. Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada. Can J Gastroenterol 2013;27:397-402. [PMID: 23862170 DOI: 10.1155/2013/801915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 556 |
Ayala G, Escobedo-Hinojosa WI, Cruz-Herrera CFL, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20(6): 1450-1469 [PMID: 24587621 DOI: 10.3748/wjg.v20.i6.1450] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 93] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 557 |
McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP; Participant Centres. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014;63:244-9. [PMID: 23665990 DOI: 10.1136/gutjnl-2013-304820] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 558 |
Farah R, Khamisy-Farah R. Association of neutrophil to lymphocyte ratio with presence and severity of gastritis due to Helicobacter pylori infection. J Clin Lab Anal. 2014;28:219-223. [PMID: 24478129 DOI: 10.1002/jcla.21669] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 559 |
Yoon SB, Park JM, Lee JY, Baeg MK, Lim CH, Kim JS, Cho YK, Lee IS, Kim SW, Choi MG. Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates. World J Gastroenterol 2014; 20(4): 1061-1066 [PMID: 24574779 DOI: 10.3748/wjg.v20.i4.1061] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 560 |
Kim JM, Zheng HM, Lee BY, Lee WK, Lee DH. Anti-Helicobacter pylori Properties of Gut Gard. Prev Nutr Food Sci. 2013;18:104-110. [PMID: 24471118 DOI: 10.3746/pnf.2013.18.2.104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 561 |
Mirzaei T, Alebouyeh M, Shokrzadeh L, Asadzadeh Aghdaei H, Farzi N, Zojaji H, Zali MR. Smoking, Proton Pump Inhibitors and Antibiotic Administration as Factors Affecting Direct Screening of Helicobacter Pylori Infection Among Patients With Dyspepsia. Arch Clin Infect Dis 2014;9. [DOI: 10.5812/archcid.15774] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 562 |
Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One. 2014;9:e85620. [PMID: 24465624 DOI: 10.1371/journal.pone.0085620] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 563 |
Sachdeva A, Rawat S, Nagpal J. Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication: A review. World J Gastroenterol 2014; 20(3): 724-737 [PMID: 24574746 DOI: 10.3748/wjg.v20.i3.724] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 564 |
Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: Which regimen first? World J Gastroenterol 2014; 20(3): 665-672 [PMID: 24574740 DOI: 10.3748/wjg.v20.i3.665] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 565 |
Wu LP, Xuan SH. Advances in research of Helicobacter pylori resistance to levofloxacin. Shijie Huaren Xiaohua Zazhi 2014; 22(2): 197-202 [DOI: 10.11569/wcjd.v22.i2.197] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 566 |
Leontiadis GI, Nyrén O. Epidemiology ofHelicobacter PyloriInfection, Peptic Ulcer Disease and Gastric Cancer. GI Epidemiology 2014. [DOI: 10.1002/9781118727072.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 567 |
Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295-314. [PMID: 21822447 DOI: 10.1586/ecp.09.8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 568 |
Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013;73:815-24. [PMID: 23625272 DOI: 10.1007/s40265-013-0053-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 569 |
Cronkright P, Ramaiya AK. Chronic Disease Management in Refugees. Refugee Health Care 2014. [DOI: 10.1007/978-1-4939-0271-2_10] [Reference Citation Analysis]
|
| 570 |
Gurney S, Carvalho L, Gonzalez C, Galaviz E, Sonstein F. An Efficacious and Cost-Effective Pharmacologic Treatment for Helicobacter pylori. The Journal for Nurse Practitioners 2014;10:22-29. [DOI: 10.1016/j.nurpra.2013.09.013] [Reference Citation Analysis]
|
| 571 |
Bergogne-bérézin E. Bacteria: Helicobacter pylori. Encyclopedia of Food Safety. Elsevier; 2014. pp. 446-9. [DOI: 10.1016/b978-0-12-378612-8.00100-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 572 |
Ruchelli ED. Gastritis and Gastropathies of Childhood. Pathology of Pediatric Gastrointestinal and Liver Disease 2014. [DOI: 10.1007/978-3-642-54053-0_3] [Reference Citation Analysis]
|
| 573 |
Jung YS, Lee SH, Park CS, Oh MJ, Kim KO, Jang BI, Jeon SW, Jung MK, Park KS, Kim ES, Cho KB, Jung JT, Kwon JG, Kim EY, Kim WJ, Yang CH. Trends in the Eradication Rates of Helicobacter pylori Infection in Daegu and Gyeongsangbuk-do, Korea: Multicenter Study over 13 Years. Korean J Gastroenterol 2014;63:82. [DOI: 10.4166/kjg.2014.63.2.82] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 574 |
Batts KP, Ketover S, Kakar S, Krasinskas AM, Mitchell KA, Wilcox R, Westerhoff M, Rank J, Gibson J, Mattia AR, Cummings OW, Davison JM, Naini BV, Dry SM, Yantiss RK; Rodger C Haggitt Gastrointestinal Pathology Society. Appropriate use of special stains for identifying Helicobacter pylori: Recommendations from the Rodger C. Haggitt Gastrointestinal Pathology Society. Am J Surg Pathol 2013;37:e12-22. [PMID: 24141174 DOI: 10.1097/PAS.0000000000000097] [Cited by in Crossref: 67] [Cited by in F6Publishing: 97] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 575 |
Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 576 |
Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337.pub2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 83] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 577 |
Suzuki RB, Lopes RA, da Câmara Lopes GA, Hung Ho T, Sperança MA. Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. BMC Gastroenterol 2013;13:164. [PMID: 24305035 DOI: 10.1186/1471-230X-13-164] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 578 |
Girón JA, Shah SL. Helicobacter pylori infection and light chain gammopathy. Clin Dev Immunol 2013;2013:348562. [PMID: 24363759 DOI: 10.1155/2013/348562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 579 |
Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter 2013;18:459-67. [PMID: 23714140 DOI: 10.1111/hel.12062] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 580 |
Yoon H, Lee DH, Kim N, Park YS, Shin CM, Kang KK, Oh DH, Jang DK, Chung JW. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 2013;28:1801-9. [PMID: 24118110 DOI: 10.1111/jgh.12397] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 581 |
Uzair S, Sutton PA, Herbert A, Hashmi K, Calvet X. Proton pump inhibitor-based triple therapies versus dual therapies for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2013. [DOI: 10.1002/14651858.cd010819] [Reference Citation Analysis]
|
| 582 |
Shih HY, Kuo FC, Wang SS, Liu YC, Wu MC, Chang YP, Chiu GF, Chang PY, Wu DC, Hsieh MC, Chen YL. Helicobacter pylori Infection and Anemia in Taiwanese Adults. Gastroenterol Res Pract 2013;2013:390967. [PMID: 24348534 DOI: 10.1155/2013/390967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 583 |
Huang J, Zhou L, Geng L, Yang M, Xu XW, Ding ZL, Mao M, Wang ZL, Li ZL, Li DY, Gong ST. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. Aliment Pharmacol Ther 2013;38:1230-5. [PMID: 24117692 DOI: 10.1111/apt.12516] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 584 |
Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes 2013;4:541-8. [PMID: 23929066 DOI: 10.4161/gmic.25930] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 585 |
Gorman DF. Towards a sustainable and fit‐for‐purpose health workforce — lessons from New Zealand. Medical Journal of Australia 2013;199. [DOI: 10.5694/mja11.11583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 586 |
Tang RS, Wu JC. Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole. Clin Interv Aging 2013;8:1433-43. [PMID: 24187492 DOI: 10.2147/CIA.S41350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 587 |
Nontakham J, Charoenram N, Upamai W, Taweechotipatr M, Suksamrarn S. Anti-Helicobacter pylori xanthones of Garcinia fusca. Arch Pharm Res 2014;37:972-7. [DOI: 10.1007/s12272-013-0266-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 588 |
Wee EW. Evidence-based approach to dyspepsia: from Helicobacter pylori to functional disease. Postgrad Med 2013;125:169-80. [PMID: 23933904 DOI: 10.3810/pgm.2013.07.2688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 589 |
Park C, Park C. Ursolic Acid Isolated from Mume Fructus Inhibits Urease Activity of Helicobacter pylori. Korean Chemical Engineering Research 2013;51:591-6. [DOI: 10.9713/kcer.2013.51.5.591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 590 |
Siao D, Somsouk M. Helicobacter pylori: evidence-based review with a focus on immigrant populations. J Gen Intern Med. 2014;29:520-528. [PMID: 24065381 DOI: 10.1007/s11606-013-2630-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 591 |
Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Park YS, Lee DH. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC Gastroenterol. 2013;13:138. [PMID: 24050512 DOI: 10.1186/1471-230x-13-138] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 592 |
Wong F, Ou G, Svarta S, Kwok R, Donaldson K, Frenette J, Enns R. Do we eradicate Helicobacter pylori in hospitalized patients with peptic ulcer disease? Can J Gastroenterol 2013;27:636-8. [PMID: 24040632 DOI: 10.1155/2013/249562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 593 |
Vilaichone RK, Yamaoka Y, Shiota S, Ratanachu-ek T, Tshering L, Uchida T, Fujioka T, Mahachai V. Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J Gastroenterol 2013; 19(33): 5508-5512 [PMID: 24023494 DOI: 10.3748/wjg.v19.i33.5508] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 594 |
Cho SJ, Choi IJ, Kook MC, Yoon H, Park S, Kim CG, Lee JY, Lee JH, Ryu KW, Kim YW. Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. Aliment Pharmacol Ther 2013;38:477-89. [PMID: 23822578 DOI: 10.1111/apt.12402] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 595 |
Jin X, Chen YP, Chen SH, Xiang Z. Association between Helicobacter Pylori infection and ulcerative colitis--a case control study from China. Int J Med Sci. 2013;10:1479-1484. [PMID: 24046521 DOI: 10.7150/ijms.6934] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 596 |
Choi IJ. Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer. Korean J Intern Med. 2013;28:525-537. [PMID: 24009446 DOI: 10.3904/kjim.2013.28.5.525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 597 |
Maeng JH, So JW, Kim J, Kim IA, Jung JH, Min K, Lee DH, Yang S. rhEGF-containing thermosensitive and mucoadhesive polymeric sol–gel for endoscopic treatment of gastric ulcer and bleeding. J Biomater Appl 2014;28:1113-21. [DOI: 10.1177/0885328213499948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 598 |
Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587. [PMID: 23926315 DOI: 10.1136/bmj.f4587] [Cited by in Crossref: 175] [Cited by in F6Publishing: 193] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 599 |
Prasertpetmanee S, Mahachai V, Vilaichone RK. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter 2013;18:270-3. [PMID: 23356886 DOI: 10.1111/hel.12041] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 600 |
Shin DW, Cho J, Kim SH, Kim YJ, Choi HC, Son KY, Park SM, Park JH, Park MS, Cho B. Preferences for the "screen and treat" strategy of Helicobacter pylori to prevent gastric cancer in healthy Korean populations. Helicobacter 2013;18:262-9. [PMID: 23384480 DOI: 10.1111/hel.12039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 601 |
Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 2013;18:274-9. [PMID: 23418857 DOI: 10.1111/hel.12046] [Cited by in Crossref: 106] [Cited by in F6Publishing: 108] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 602 |
Xiang Z, Chen YP, Ye YF, Ma KF, Chen SH, Zheng L, Yang YD, Jin X. Helicobacter pylori and Crohn’s disease: A retrospective single-center study from China. World J Gastroenterol 2013; 19(28): 4576-4581 [PMID: 23901235 DOI: 10.3748/wjg.v19.i28.4576] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 603 |
Tonkić A, Tonkić M, Brnić D. Increasing Prevalence of Primary Clarithromycin Resistance in Helicobacter pylori Strains in Split, Croatia. Journal of Chemotherapy 2013;21:598-9. [DOI: 10.1179/joc.2009.21.5.598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 604 |
Zhang G, Zou J, Liu F, Bao Z, Dong F, Huang Y, Yin S. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res. 2013;46:607-613. [PMID: 23903685 DOI: 10.1590/1414-431x20132817] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 605 |
Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther. 2011;9:581-588. [PMID: 21819326 DOI: 10.1586/eri.11.80] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 606 |
Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013;145:121-128.e1. [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050] [Cited by in Crossref: 138] [Cited by in F6Publishing: 154] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 607 |
Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211-223. [PMID: 23331077 DOI: 10.1517/14656566.2013.763926] [Cited by in Crossref: 35] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 608 |
Tajalli R, Nobakht M, Mohammadi-Barzelighi H, Agah S, Rastegar-Lari A, Sadeghipour A. The immunohistochemistry and toluidine blue roles for Helicobacter pylori detection in patients with gastritis. Iran Biomed J. 2013;17:36-41. [PMID: 23279833 DOI: 10.6091/ibj.1094.2012] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 609 |
Lee HJ, Kim JI, Cheung DY, Kim TH, Jun EJ, Oh JH, Chung WC, Kim BW, Kim SS, Park SH. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis. 2013;208:1123-1130. [PMID: 23801607 DOI: 10.1093/infdis/jit287] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 610 |
Moshiree B, Barboza J, Talley N. An update on current pharmacotherapy options for dyspepsia. Expert Opinion on Pharmacotherapy 2013;14:1737-53. [DOI: 10.1517/14656566.2013.809063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 611 |
Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 2013;18:180-6. [PMID: 23305083 DOI: 10.1111/hel.12034] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 612 |
Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013;18:206-14. [PMID: 23241101 DOI: 10.1111/hel.12031] [Cited by in Crossref: 181] [Cited by in F6Publishing: 176] [Article Influence: 18.1] [Reference Citation Analysis]
|
| 613 |
Meltzer AC, Pierce R, Cummings DA, Pines JM, May L, Smith MA, Marcotte J, McCarthy ML. Rapid (13)C Urea Breath Test to Identify Helicobacter pylori Infection in Emergency Department Patients with Upper Abdominal Pain. West J Emerg Med 2013;14:278-82. [PMID: 23687549 DOI: 10.5811/westjem.2012.12.15173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 614 |
Triadafilopoulos G, Roorda AK, Akiyama J. Indications and safety of proton pump inhibitor drug use in patients with cancer. Expert Opin Drug Saf. 2013;12:659-672. [PMID: 23647006 DOI: 10.1517/14740338.2013.797961] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 615 |
Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-analysis of randomized clinical trials. PLoS One. 2013;8:e62162. [PMID: 23646118 DOI: 10.1371/journal.pone.0062162] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 616 |
O'Connor A, Taneike I, Nami A, Fitzgerald N, Ryan B, Breslin N, O'Connor H, McNamara D, Murphy P, O'Morain C. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci. 2013;182:693-695. [PMID: 23625165 DOI: 10.1007/s11845-013-0957-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 617 |
Molina-Infante J, Gisbert JP. [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. Gastroenterol Hepatol. 2013;36:375-381. [PMID: 23623461 DOI: 10.1016/j.gastrohep.2013.02.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 618 |
Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol 2013;36:340-74. [PMID: 23601856 DOI: 10.1016/j.gastrohep.2013.01.011] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 619 |
Schmitt BH, Regner M, Mangold KA, Thomson RB, Kaul KL. PCR detection of clarithromycin-susceptible and -resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies. Mod Pathol. 2013;26:1222-1227. [PMID: 23579617 DOI: 10.1038/modpathol.2013.48] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 620 |
Zhang JX, Wang K, Mao ZF, Fan X, Jiang DL, Chen M, Cui L, Sun K, Dang SC. Application of liposomes in drug development--focus on gastroenterological targets. Int J Nanomedicine. 2013;8:1325-1334. [PMID: 23630417 DOI: 10.2147/ijn.s42153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 621 |
Deng B, Li Y, Zhang Y, Bai L, Yang P. Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis. Carcinogenesis. 2013;34:1189-1195. [PMID: 23568955 DOI: 10.1093/carcin/bgt114] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 622 |
Cosme A, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, Piñeiro L, Recasens M, Ibarra B, Sarasqueta C, Bujanda L. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clinical Microbiology and Infection 2013;19:379-83. [DOI: 10.1111/j.1469-0691.2012.03844.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 623 |
Zhou X, Wu J, Zhang G. Association between Helicobacter pylori and asthma: a meta-analysis. Eur J Gastroenterol Hepatol 2013;25:460-8. [PMID: 23242126 DOI: 10.1097/MEG.0b013e32835c280a] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 624 |
Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JM, Jung HC. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. Helicobacter 2013;18:135-42. [PMID: 23066652 DOI: 10.1111/hel.12018] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 625 |
Gisbert JP, Calvet X. Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. Clin Transl Gastroenterol 2013;4:e32. [PMID: 23535826 DOI: 10.1038/ctg.2013.3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 626 |
Puram S, Suh HC, Kim SU, Bethapudi B, Joseph JA, Agarwal A, Kudiganti V. Effect of GutGard in the Management of Helicobacter pylori: A Randomized Double Blind Placebo Controlled Study. Evid Based Complement Alternat Med. 2013;2013:263805. [PMID: 23606875 DOI: 10.1155/2013/263805] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 627 |
Navarro-Rodriguez T, Silva FM, Barbuti RC, Mattar R, Moraes-Filho JP, de Oliveira MN, Bogsan CS, Chinzon D, Eisig JN. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013;13:56. [PMID: 23530767 DOI: 10.1186/1471-230x-13-56] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 628 |
Navarro-Rodriguez T, Silva FM, Barbuti RC, Mattar R, Moraes-Filho JP, de Oliveira MN, Bogsan CS, Chinzon D, Eisig JN. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013;13:56. [PMID: 23311418 DOI: 10.1186/1471-230x-13-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 629 |
Singhi S, Jain P, Jayashree M, Lal S. Approach to a child with upper gastrointestinal bleeding. Indian J Pediatr. 2013;80:326-333. [PMID: 23504479 DOI: 10.1007/s12098-013-0987-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 630 |
Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol 2013;47:233-8. [PMID: 23090037 DOI: 10.1097/MCG.0b013e3182676e2b] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 631 |
Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:168-74. [PMID: 23358394 DOI: 10.1038/nrgastro.2013.9] [Cited by in Crossref: 121] [Cited by in F6Publishing: 107] [Article Influence: 12.1] [Reference Citation Analysis]
|
| 632 |
Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. J Clin Gastroenterol 2013;47:228-32. [PMID: 22858517 DOI: 10.1097/MCG.0b013e31826015b0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 633 |
Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM, Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA 2013;309:578-86. [PMID: 23403682 DOI: 10.1001/jama.2013.311] [Cited by in Crossref: 55] [Cited by in F6Publishing: 62] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 634 |
Sepulveda AR. Helicobacter, Inflammation, and Gastric Cancer. Curr Pathobiol Rep. 2013;1:9-18. [PMID: 23687623 DOI: 10.1007/s40139-013-0009-8] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 635 |
Mapel D, Roberts M, Overhiser A, Mason A. The epidemiology, diagnosis, and cost of dyspepsia and Helicobacter pylori gastritis: a case-control analysis in the Southwestern United States. Helicobacter 2013;18:54-65. [PMID: 23067108 DOI: 10.1111/j.1523-5378.2012.00988.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 636 |
Couturier MR. The Evolving Challenges of Helicobacter pylori Disease, Diagnostics, and Treatment, Part I. Clinical Microbiology Newsletter 2013;35:19-24. [DOI: 10.1016/j.clinmicnews.2013.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 637 |
Bourne C, Charpiat B, Charhon N, Bertin C, Gouraud A, Mouchoux C, Skalli S, Janoly-dumenil A. Effets indésirables émergents des inhibiteurs de la pompe à protons. La Presse Médicale 2013;42:e53-62. [DOI: 10.1016/j.lpm.2012.09.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 638 |
Liu MK, Wu IC, Lu CY, Kuo CH, Yu FJ, Liu CJ, Hsu PI, Hsu WH, Su YC, Chen A. Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens. Kaohsiung J Med Sci. 2013;29:379-384. [PMID: 23768702 DOI: 10.1016/j.kjms.2012.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 639 |
Koleilat I, Nigam A. Gastrointestinal Lymphomas. Shackelford's Surgery of the Alimentary Tract 2013. [DOI: 10.1016/b978-1-4377-2206-2.00082-8] [Reference Citation Analysis]
|
| 640 |
von Renteln D, Vassiliou MC. Endoscopic Tools/Techniques for Tissue Sampling. Principles of Flexible Endoscopy for Surgeons 2013. [DOI: 10.1007/978-1-4614-6330-6_7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 641 |
Kim CG. Helicobacter pylori and Hematologic Diseases. Korean J Med 2013;84:769. [DOI: 10.3904/kjm.2013.84.6.769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 642 |
Harada S, Sepulveda AR. Molecular Mechanisms and Pathology of Gastric Carcinogenesis: Sporadic Cancers. Molecular Pathology Library 2013. [DOI: 10.1007/978-1-4614-6015-2_5] [Reference Citation Analysis]
|
| 643 |
Krishnan A, Prabhu Ponnusamy R, Ramakrishnan V. Long-term Acid Suppression Therapy: Its Influence on Gastric Mucosa. Euroasian Journal of Hepato-Gastroenterology 2013;3:19-22. [DOI: 10.5005/jp-journals-10018-1055] [Reference Citation Analysis]
|
| 644 |
H. Ferri's Clinical Advisor 2013 2013. [DOI: 10.1016/b978-0-323-08373-7.00017-0] [Reference Citation Analysis]
|
| 645 |
Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:25-32. [PMID: 23090045 DOI: 10.1097/MCG.0b013e318266f6cf] [Cited by in Crossref: 109] [Cited by in F6Publishing: 117] [Article Influence: 10.9] [Reference Citation Analysis]
|
| 646 |
Muri EMF, Barros TG. Hydroxamic Acids as Inhibitors of Urease in the Treatment of Helicobacter pylori Infections. Hydroxamic Acids 2013. [DOI: 10.1007/978-3-642-38111-9_9] [Reference Citation Analysis]
|
| 647 |
Zucca E, Bertoni F, Cavalli F. MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma). Lymphoma 2013. [DOI: 10.1007/978-1-62703-408-1_6] [Reference Citation Analysis]
|
| 648 |
Simadibrata M, Syam AF, Rani A, Wanandi SI, Fauzi A, Abdullah M. Anti free radical & anti inflammatory effect of rebamipide in chronic gastritis. OJGas 2013;03:72-7. [DOI: 10.4236/ojgas.2013.31011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 649 |
Campbell S, Landry ML. Rapid Antigen Tests. Advanced Techniques in Diagnostic Microbiology 2013. [DOI: 10.1007/978-1-4614-3970-7_3] [Reference Citation Analysis]
|
| 650 |
Schirmer B, Hallowell PT. Reoperative Surgery of the Stomach and Duodenum. Shackelford's Surgery of the Alimentary Tract 2013. [DOI: 10.1016/b978-1-4377-2206-2.00077-4] [Reference Citation Analysis]
|
| 651 |
Girman A. Biomarkers for Stool Analysis. Textbook of Natural Medicine 2013. [DOI: 10.1016/b978-1-4377-2333-5.00027-4] [Reference Citation Analysis]
|
| 652 |
Mannon PJ. Immunologic diseases of the gastrointestinal tract. Clinical Immunology 2013. [DOI: 10.1016/b978-0-7234-3691-1.00088-x] [Reference Citation Analysis]
|
| 653 |
Liou J, Chen C, Chen M, Chen C, Chang C, Fang Y, Lee J, Hsu S, Luo J, Chang W, Hsu Y, Tseng C, Tseng P, Wang H, Yang U, Shun C, Lin J, Lee Y, Wu M. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. The Lancet 2013;381:205-13. [DOI: 10.1016/s0140-6736(12)61579-7] [Cited by in Crossref: 171] [Cited by in F6Publishing: 167] [Article Influence: 17.1] [Reference Citation Analysis]
|
| 654 |
Wang S, Zhang W, Reineks E. Breath Tests for Detection of Helicobacter pylori and Aspergillus fumigatus. Advanced Techniques in Diagnostic Microbiology 2013. [DOI: 10.1007/978-1-4614-3970-7_2] [Reference Citation Analysis]
|
| 655 |
Lan HC, Chen TS, Li AF, Chang FY, Lin HC. Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. BMC Gastroenterol. 2012;12:182. [PMID: 23272897 DOI: 10.1186/1471-230x-12-182] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 656 |
Saleh P, Zarrintan A, Zeinal Zade AH, Piri R, Mohammadi S, Naghavi-behzad M. Efficiency of Helicobacter pylori Infection Treatment Protocol: Clarithromycin, Amoxicillin and Omeprazole. Arch Clin Infect Dis 2012;8:14-7. [DOI: 10.5812/archcid.14408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 657 |
El-Omar EM. Iron deficiency and Helicobacter pylori-induced gastric cancer: too little, too bad. J Clin Invest 2013;123:113-4. [PMID: 23257355 DOI: 10.1172/JCI67200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 658 |
Zinzani PL. The many faces of marginal zone lymphoma. Hematology 2012;2012:426-32. [DOI: 10.1182/asheducation.v2012.1.426.3798535] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 659 |
Yoon JH, Baik GH, Sohn KM, Kim DY, Kim YS, Suk KT, Kim JB, Kim DJ, Kim JB, Shin WG, Kim HY, Baik IH, Jang HJ. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012; 18(45): 6628-6634 [PMID: 23236238 DOI: 10.3748/wjg.v18.i45.6628] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 660 |
El-zimaity H, Riddell RH. Inflammatory Disorders of the Stomach. Morson and Dawson's Gastrointestinal Pathology 2012. [DOI: 10.1002/9781118399668.ch11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 661 |
Kim HD, Kim do H, Park H, Kim WJ, Ahn YS, Lee YJ, Park SM, Seo ES, Park C, Kim YH. Detection of Helicobacter pylori in Gastric Aspirates Using a Monoclonal Antibody-Based Test. Gut Liver. 2013;7:30-34. [PMID: 23423538 DOI: 10.5009/gnl.2013.7.1.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 662 |
Salvador JA, Figueiredo SA, Pinto RM, Silvestre SM. Bismuth compounds in medicinal chemistry. Future Med Chem 2012;4:1495-523. [PMID: 22857536 DOI: 10.4155/fmc.12.95] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 663 |
Qian J, Ye F, Zhang J, Yang YM, Tu HM, Jiang Q, Shang L, Pan XL, Shi RH, Zhang GX. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. Helicobacter 2012;17:478-85. [PMID: 23067317 DOI: 10.1111/j.1523-5378.2012.00993.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 664 |
Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y, Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial. Helicobacter 2012;17:458-65. [PMID: 23066868 DOI: 10.1111/j.1523-5378.2012.00971.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 665 |
den Hollander WJ, Kuipers EJ. Current pharmacotherapy options for gastritis. Expert Opin Pharmacother. 2012;13:2625-2636. [PMID: 23167300 DOI: 10.1517/14656566.2012.747510] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 666 |
Greenberg ER, Chey WD. Defining the role of sequential therapy for H pylori infection. Lancet. 2013;381:180-182. [PMID: 23158881 DOI: 10.1016/s0140-6736(12)61849-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 667 |
Guariso G, Gasparetto M. Update on Peptic Ulcers in the Pediatric Age. Ulcers 2012;2012:1-9. [DOI: 10.1155/2012/896509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 668 |
Chung JW, Jung YK, Kim YJ, Kwon KA, Kim JH, Lee JJ, Lee SM, Hahm KB, Lee SM, Jeong JY, Yun SC. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012;27:1675-80. [PMID: 22849546 DOI: 10.1111/j.1440-1746.2012.07249.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 669 |
Tolone S, Pellino V, Vitaliti G, Lanzafame A, Tolone C. Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital J Pediatr. 2012;38:63. [PMID: 23114016 DOI: 10.1186/1824-7288-38-63] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 670 |
Heineman J, Bubenik S, McClave S, Martindale R. Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases? Curr Gastroenterol Rep. 2012;14:343-348. [PMID: 22763792 DOI: 10.1007/s11894-012-0274-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 671 |
Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2013;68:450-456. [PMID: 23099849 DOI: 10.1093/jac/dks407] [Cited by in Crossref: 56] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 672 |
Jeong MH, Chung JW, Lee SJ, Ha M, Jeong SH, Na S, Na BS, Park SK, Kim YJ, Kwon KA. [Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori]. Korean J Gastroenterol. 2012;59:401-406. [PMID: 22735872 DOI: 10.4166/kjg.2012.59.6.401] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 673 |
Verma S, Sharma D, Kanwar P, Sohn W, Mohanty SR, Tortolani AJ, Gorecki P. Prevalence of Helicobacter pylori infection in bariatric patients: a histologic assessment. Surg Obes Relat Dis. 2013;9:679-685. [PMID: 23246321 DOI: 10.1016/j.soard.2012.10.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 674 |
Abdulqawi K, El-Mahalaway AM, Abdelhameed A, Abdelwahab AA. Correlation of serum antibody titres with invasive methods for rapid detection of Helicobacter pylori infections in symptomatic children. Int J Exp Pathol. 2012;93:295-304. [PMID: 22804766 DOI: 10.1111/j.1365-2613.2012.00831.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 675 |
Olafsson S, Patel B, Jackson C, Cai J. Helicobacter pylori breath testing in an open access system has a high rate of potentially false negative results due to protocol violations. Helicobacter 2012;17:391-5. [PMID: 22967123 DOI: 10.1111/j.1523-5378.2012.00964.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 676 |
Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study. Helicobacter 2012;17:374-81. [PMID: 22967121 DOI: 10.1111/j.1523-5378.2012.00960.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 677 |
de Korwin JD. [New recommendations for the diagnosis and the treatment of Helicobacter pylori infection]. Presse Med. 2013;42:309-317. [PMID: 23021657 DOI: 10.1016/j.lpm.2012.07.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 678 |
Figura N, Marcolongo R, Cavallo G, Santucci A, Collodel G, Spreafico A, Moretti E. Polysorbate 80 and Helicobacter pylori: a microbiological and ultrastructural study. BMC Microbiol 2012;12:217. [PMID: 22998649 DOI: 10.1186/1471-2180-12-217] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 679 |
Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012;5:151-157. [PMID: 23028235 DOI: 10.2147/ceg.s25416] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 680 |
Lin MH, Cheng HT, Chuang WY, Yu LK, Tsou YK, Lee MS. Histological examination of ulcer margin for diagnosing Helicobacter pylori infection in patients with gastric ulcers. Ann Diagn Pathol. 2013;17:63-66. [PMID: 22981783 DOI: 10.1016/j.anndiagpath.2012.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 681 |
Kobayashi Y, Hatta Y, Hojo A, Kura Y, Uchino Y, Takahashi H, Kiso S, Hirabayashi Y, Yagi M, Kodaira H, Kurita D, Tanaka T, Miura K, Iriyama N, Kobayashi S, Sawada U, Sugitani M, Takeuchi J. Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Exp Ther Med 2012;3:304-8. [PMID: 22969886 DOI: 10.3892/etm.2011.387] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 682 |
Sereni G, Azzolini F, Camellini L, Formisano D, Decembrino F, Iori V, Tioli C, Cavina M, Di Mario F, Bedogni G, Sassatelli R. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. World J Gastroenterol 2012; 18(33): 4542-4548 [PMID: 22969227 DOI: 10.3748/wjg.v18.i33.4542] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 683 |
Segarra-newnham M, Coakley C. Salvage Options for Eradication of Helicobacter pylori During Tetracycline Backorder. Journal of Pharmacy Technology 2012;28:187-192. [DOI: 10.1177/875512251202800502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 684 |
Shmuely H, Friedman M, Aronov I, Bernstine H, Yahav J, Samra Z, Chodick G, Hamilton CS, Samuelson CG, Groshar D. The effect of radioiodine on eradication of Helicobacter pylori infection in patients with thyroid cancer—A pilot study. Operative Techniques in Otolaryngology-Head and Neck Surgery 2012;23:206-210. [DOI: 10.1016/j.otot.2012.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 685 |
Epstein A, Wing DA, Ouzounian JG, Miller DA, Lee RH. Helicobacter pylori and thrombocytopenia in the pregnant hispanic population. The Journal of Maternal-Fetal & Neonatal Medicine 2012;25:2588-90. [DOI: 10.3109/14767058.2012.713054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 686 |
González-Huezo MS, Rojas-Sánchez A, Rosales-Solís AA, Miranda-Cordero RM, Hinojosa-Ruiz A, Mejía-García E, Cruz-González EG. [Helicobacter pylori eradication frequency with the conventional triple therapy in adult patients at the Centro Médico Issemym]. Rev Gastroenterol Mex. 2012;77:114-118. [PMID: 22921101 DOI: 10.1016/j.rgmx.2012.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 687 |
Tarkhashvili N, Chakvetadze N, Mebonia N, Chubinidze M, Bakanidze L, Shengelidze V, Mirtskhulava M, Chachava T, Katsitadze G, Gabunia U, Kordzaia D, Imnadze P, Guarner J, Sobel J. Traditional risk factors for Helicobacter pylori infection not found among patients undergoing diagnostic upper endoscopy-Republic of Georgia, 2007-2008. Int J Infect Dis 2012;16:e697-702. [PMID: 22867956 DOI: 10.1016/j.ijid.2012.05.1031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 688 |
Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter 2012;17:269-76. [PMID: 22759326 DOI: 10.1111/j.1523-5378.2012.00947.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 689 |
Manfredi M, Bizzarri B, de'Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012;17:246-53. [PMID: 22759323 DOI: 10.1111/j.1523-5378.2012.00945.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 690 |
Lee YC, Tseng PH, Liou JM, Chen MJ, Chen CC, Tu CH, Chiang TH, Chiu HM, Lai CF, Ho JC. Performance of a one-step fecal sample-based test for diagnosis of Helicobacter pylori infection in primary care and mass screening settings. J Formos Med Assoc. 2014;113:899-907. [PMID: 25530066 DOI: 10.1016/j.jfma.2012.05.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 691 |
Cammarota G, Sanguinetti M, Gallo A, Posteraro B. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Aliment Pharmacol Ther 2012;36:222-30. [PMID: 22650647 DOI: 10.1111/j.1365-2036.2012.05165.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 692 |
Tang RS, Chan FK. Therapeutic Management of Recurrent Peptic Ulcer Disease: . Drugs 2012;72:1605-16. [DOI: 10.2165/11634850-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 693 |
Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 2012;17:282-5. [PMID: 22759328 DOI: 10.1111/j.1523-5378.2012.00953.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 694 |
Lozano Bretón CE. Dolor abdominal agudo: Enfoque para el médico de atención primaria. MedUNAB 2012;15:113-122. [DOI: 10.29375/01237047.1652] [Reference Citation Analysis]
|
| 695 |
Gasparetto M, Pescarin M, Guariso G. Helicobacter pylori Eradication Therapy: Current Availabilities. ISRN Gastroenterol. 2012;2012:186734. [PMID: 22900197 DOI: 10.5402/2012/186734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 696 |
Shih HY, Wang SS, Kuo CH, Kuo FC, Chen YY, Wu MC, Weng BC, Lee YC, Hu CT, Wu DC, Chen YH. Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese Population. Gastroenterol Res Pract 2012;2012:674324. [PMID: 22829808 DOI: 10.1155/2012/674324] [Reference Citation Analysis]
|
| 697 |
Wu W, Yang Y, Sun G. Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract 2012;2012:723183. [PMID: 22829809 DOI: 10.1155/2012/723183] [Cited by in Crossref: 54] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 698 |
Yuan Y, Leontiadis GI. Levofloxacin-based three-antibiotic regimen for H. pylori eradication. Am J Gastroenterol 2012;107:1106-7; author reply 1107. [PMID: 22764031 DOI: 10.1038/ajg.2012.109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 699 |
Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012;2012:168361. [PMID: 22792095 DOI: 10.1155/2012/168361] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 700 |
Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926.Epub2012Jun19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 701 |
Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 702 |
Roesler BM, Costa SC, Zeitune JM. Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer. ISRN Gastroenterol. 2012;2012:935410. [PMID: 22778979 DOI: 10.5402/2012/935410] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 703 |
Roberts BP, Miller BR 3rd, Roitberg AE, Merz KM Jr. Wide-open flaps are key to urease activity. J Am Chem Soc 2012;134:9934-7. [PMID: 22670767 DOI: 10.1021/ja3043239] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 704 |
Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A, González-Colominas E, Aresti-Zárate S. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother. 2012;67:2254-2259. [PMID: 22687889 DOI: 10.1093/jac/dks209] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 705 |
Suzuki RB, Almeida CM, Sperança MA. Absence of Helicobacter pylori high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. BMC Gastroenterol 2012;12:49. [PMID: 22594560 DOI: 10.1186/1471-230X-12-49] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 706 |
Khan A, Farooqui A, Manzoor H, Akhtar SS, Quraishy MS, Kazmi SU. Antibiotic resistance and cagA gene correlation: A looming crisis of Helicobacter pylori. World J Gastroenterol 2012; 18(18): 2245-2252 [PMID: 22611319 DOI: 10.3748/wjg.v18.i18.2245] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 707 |
Rozza AL, Hiruma-Lima CA, Tanimoto A, Pellizzon CH. Morphologic and pharmacological investigations in the epicatechin gastroprotective effect. Evid Based Complement Alternat Med 2012;2012:708156. [PMID: 22666296 DOI: 10.1155/2012/708156] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 708 |
Milani M, Ghotaslou R, Akhi MT, Nahaei MR, Hasani A, Somi MH, Rafeey M, Sharifi Y. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother. 2012;18:848-852. [PMID: 22581031 DOI: 10.1007/s10156-012-0425-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 709 |
Gill RS, Collins JS, Talley NJ. Management of noncardiac chest pain in women. Womens Health (Lond) 2012;8:131-43; quiz 144-5. [PMID: 22375717 DOI: 10.2217/whe.12.3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 710 |
Lash RH, Genta RM. Gastritis. Textbook of Clinical Gastroenterology and Hepatology 2012. [DOI: 10.1002/9781118321386.ch33] [Reference Citation Analysis]
|
| 711 |
Marshall BJ, Windsor HM, Kimura K. H. Pylori: Its Diseases and Management. Textbook of Clinical Gastroenterology and Hepatology 2012. [DOI: 10.1002/9781118321386.ch22] [Reference Citation Analysis]
|
| 712 |
Kessenich CR, Erigo-backsman RC. Gastritis and noninvasive testing for Helicobacter pylori. The Nurse Practitioner 2012;37:7-9. [DOI: 10.1097/01.npr.0000412901.86759.5c] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 713 |
O'Connor JP, O'Morain CA. Letter: the ethics of using inferior regimens in H. pylori randomised trials - invited comment. Aliment Pharmacol Ther 2012;35:854-6; discussion 858. [PMID: 22404412 DOI: 10.1111/j.1365-2036.2011.04951.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 714 |
Leung Ki EL, Chan FK. Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice. Best Pract Res Clin Gastroenterol 2012;26:163-72. [PMID: 22542154 DOI: 10.1016/j.bpg.2012.01.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 715 |
Silva O, Viegas S, de Mello-Sampayo C, Costa MJ, Serrano R, Cabrita J, Gomes ET. Anti-Helicobacter pylori activity of Terminalia macroptera root. Fitoterapia. 2012;83:872-876. [PMID: 22465506 DOI: 10.1016/j.fitote.2012.03.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 716 |
Kim JS, Jang YR, Lee JW, Kim JY, Jung YK, Chung DH, Kwon OS, Kim YS, Choi DJ, Kim JH. A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage. Korean J Hepatol. 2011;17:229-232. [PMID: 22102391 DOI: 10.3350/kjhep.2011.17.3.229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 717 |
Cerqueira RM, Manso MC, Correia MR, Fernandes CD, Vilar H, Nora M, Martins P. Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery--fourteen days superior to seven days? Obes Surg. 2011;21:1377-1381. [PMID: 20838918 DOI: 10.1007/s11695-010-0254-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 718 |
Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. [PMID: 22457599 DOI: 10.2147/ceg.s25419] [Cited by in Crossref: 97] [Cited by in F6Publishing: 107] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 719 |
Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, Pedrazzoli Jr J. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol. 2011;48:261-264. [PMID: 22147131 DOI: 10.1590/s0004-28032011000400008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 720 |
Kuo SH, Yeh KH, Wu MS, Lin CW, Hsu PN, Wang HP, Chen LT, Cheng AL. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119:4838-4844; quiz 5057. [PMID: 22403257 DOI: 10.1182/blood-2012-01-404194] [Cited by in Crossref: 99] [Cited by in F6Publishing: 108] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 721 |
Tsay FW, Tseng HH, Hsu PI, Wang KM, Lee CC, Chang SN, Wang HM, Yu HC, Chen WC, Peng NJ, Lai KH, Wu DC. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol 2012;27:498-503. [PMID: 21871025 DOI: 10.1111/j.1440-1746.2011.06885.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 722 |
Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345-60; quiz 361. [PMID: 22310222 DOI: 10.1038/ajg.2011.480] [Cited by in Crossref: 483] [Cited by in F6Publishing: 505] [Article Influence: 43.9] [Reference Citation Analysis]
|
| 723 |
Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, Song HJ, Jung HY, Kim JH. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol 2012;27:493-7. [PMID: 21793912 DOI: 10.1111/j.1440-1746.2011.06874.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 724 |
Oh HS, Lee DH, Seo JY, Cho YR, Kim N, Jeoung SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Cho HJ, Jung HC, Song IS. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol 2012;27:504-9. [PMID: 21916989 DOI: 10.1111/j.1440-1746.2011.06922.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 725 |
Fujioka T, Aoyama N, Sakai K, Miwa Y, Kudo M, Kawashima J, Matsubara Y, Miwa J, Yakabi K. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol 2012;47:276-83. [PMID: 22065160 DOI: 10.1007/s00535-011-0487-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 726 |
Rayner CK, Talley NJ, Horowitz M. Stomach bugs and diabetes: an astounding observation or just confounding? Diabetes Care 2012;35:463-4. [PMID: 22355017 DOI: 10.2337/dc11-2470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 727 |
Miranda WR, Smith JM, Burton MC. 33-Year-Old Woman With Epigastric Pain and Hematemesis. Mayo Clinic Proceedings 2012;87:194-197. [DOI: 10.1016/j.mayocp.2011.10.004] [Reference Citation Analysis]
|
| 728 |
Georgopoulos S, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, Spiliadi C, Fragou P, Skorda L, Karatapanis S. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. Helicobacter 2012;17:49-53. [PMID: 22221616 DOI: 10.1111/j.1523-5378.2011.00911.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 729 |
Gargallo C, Serrano T, Gomollón F. Protocolo de seguimiento de la infección por Helicobacter pylori. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:131-134. [DOI: 10.1016/s0304-5412(12)70273-1] [Reference Citation Analysis]
|
| 730 |
Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter 2012;17:43-8. [PMID: 22221615 DOI: 10.1111/j.1523-5378.2011.00896.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 731 |
Gargallo C, Aranguren García P, Gomollón F. Infección por Helicobacter pylori. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:90-96. [DOI: 10.1016/s0304-5412(12)70266-4] [Reference Citation Analysis]
|
| 732 |
Leontiadis GI, Sharma VK. Hematemesis, Melena, and Occult Bleeding/Anemia. Problem‐Based Approach to Gastroenterology and Hepatology 2012. [DOI: 10.1002/9781444346381.ch5] [Reference Citation Analysis]
|
| 733 |
Heidelbaugh JJ. Gastroenterology. Textbook of Family Medicine 2012. [DOI: 10.1016/b978-1-4377-1160-8.10038-7] [Reference Citation Analysis]
|
| 734 |
Vachon MC, Dieterich DT. Gastrointestinal disorders in HIV including diarrhea. Sande's HIV/AIDS Medicine 2012. [DOI: 10.1016/b978-1-4557-0695-2.00018-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 735 |
Kalman RS, Wolf JL. Gastrointestinal Manifestations of Systemic Lupus Erythematosus. Lupus Erythematosus 2012. [DOI: 10.1007/978-1-4614-1189-5_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 736 |
Karczewska E, Klesiewicz K, Skiba I, Wojtas-bonior I, Sito E, Czajecki K, Zwolińska-wcisło M, Budak A. Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. Gastroenterology Research and Practice 2012;2012:1-7. [DOI: 10.1155/2012/418010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 737 |
Jung SW. IsHelicobacter pyloriEradication Effective in Managing Functional Dyspepsia? Korean J Gastroenterol 2012;59:200. [DOI: 10.4166/kjg.2012.59.2.200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 738 |
Warner EA, Herold AH. Interpreting Laboratory Tests. Textbook of Family Medicine 2012. [DOI: 10.1016/b978-1-4377-1160-8.10015-6] [Reference Citation Analysis]
|
| 739 |
Nekhai S, Gordeuk VR. Iron Metabolism in Cancer and Infection. Iron Physiology and Pathophysiology in Humans 2012. [DOI: 10.1007/978-1-60327-485-2_24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 740 |
Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012;35:209-21. [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 129] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 741 |
Hill PG. Gastric, Pancreatic, and Intestinal Function. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics 2012. [DOI: 10.1016/b978-1-4160-6164-9.00051-2] [Reference Citation Analysis]
|
| 742 |
Yoon SY, Shim K. Indications forHelicobacter pyloriEradication Therapy. Korean J Helicobacter Up Gastrointest Res 2012;12:213. [DOI: 10.7704/kjhugr.2012.12.4.213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 743 |
Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB, Park KS, Lee SH, Kim KO, Jeon SW. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther 2012;35:56-65. [PMID: 22066530 DOI: 10.1111/j.1365-2036.2011.04902.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 744 |
Miura S, Hokari R. Seeking an optimal eradication therapy for Helicobacter pylori infection. J Gastroenterol Hepatol 2012;27:7-9. [PMID: 22188025 DOI: 10.1111/j.1440-1746.2011.06953.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 745 |
Hemstreet B. Gastrointestinal Disorders: A Focus on Acid-Suppressive Agents. Pharmaceutical Sciences Encyclopedia 2011. [DOI: 10.1002/9780470571224.pse452] [Reference Citation Analysis]
|
| 746 |
Kim SY, Jung SW. [Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol 2011;58:67-73. [PMID: 21873820 DOI: 10.4166/kjg.2011.58.2.67] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 747 |
Yogeswaran K, Chen G, Cohen L, Cooper MA, Yong E, Hsieh E, Rowsell C, Saibil F, Tinmouth J. How well is Helicobacter pylori treated in usual practice? Can J Gastroenterol 2011;25:543-6. [PMID: 22059158 DOI: 10.1155/2011/647904] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 748 |
Koussoulas V, Giamarellos-Bourboulis EJ, Barbatzas C, Pimentel M. Serum sTREM-1 as a surrogate marker of treatment outcome in patients with peptic ulcer disease. Dig Dis Sci 2011;56:3590-5. [PMID: 21633832 DOI: 10.1007/s10620-011-1761-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 749 |
Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011;34:1255-68. [PMID: 22017749 DOI: 10.1111/j.1365-2036.2011.04887.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 750 |
Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011;16:420-6. [PMID: 22059392 DOI: 10.1111/j.1523-5378.2011.00867.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 751 |
Suzuki H, Matsuzaki J, Hibi T. Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for Helicobacter pylori eradication? Expert Rev Clin Pharmacol 2011;4:579-82. [PMID: 22114887 DOI: 10.1586/ecp.11.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 752 |
Makobongo MO, Gancz H, Carpenter BM, McDaniel DP, Merrell DS. The oligo-acyl lysyl antimicrobial peptide C12K-2β12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori. Antimicrob Agents Chemother. 2012;56:378-390. [PMID: 22064541 DOI: 10.1128/aac.00689-11] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 753 |
Garcia M, Raymond J, Garnier M, Cremniter J, Burucoa C. Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. Antimicrob Agents Chemother. 2012;56:550-551. [PMID: 22064536 DOI: 10.1128/AAC.05243-11] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 754 |
Watson JB, Moss SF. Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. Am J Gastroenterol 2011;106:1976-7. [PMID: 22056576 DOI: 10.1038/ajg.2011.309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 755 |
Gisbert JP, Calvet X. Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther 2011;34:1047-62. [PMID: 21919927 DOI: 10.1111/j.1365-2036.2011.04839.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 756 |
Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG, Kim KH, Kim HY, Baik GH. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011;34:1098-105. [PMID: 21923713 DOI: 10.1111/j.1365-2036.2011.04843.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 757 |
Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011;106:1970-5. [PMID: 21989146 DOI: 10.1038/ajg.2011.306] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 758 |
Oxentenko AS, Bundrick JB, Litin SC. Clinical pearls in gastroenterology 2011. Mayo Clin Proc 2011;86:1104-8. [PMID: 22033255 DOI: 10.4065/mcp.2011.0399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 759 |
Yoon H, Kim N, Lee HS, Shin CM, Park YS, Lee DH, Jung HC, Song IS. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter 2011;16:382-8. [PMID: 21923684 DOI: 10.1111/j.1523-5378.2011.00859.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 760 |
Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am 2011;21:613-35. [PMID: 21944414 DOI: 10.1016/j.giec.2011.07.011] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 761 |
Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011;27:565-70. [PMID: 21946029 DOI: 10.1097/MOG.0b013e32834bb818] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 762 |
Mansour NM, Hashash JG, El-Halabi M, Ghaith O, Maasri K, Sukkarieh I, Malli A, Sharara AI. A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2011;23:865-70. [PMID: 21811161 DOI: 10.1097/MEG.0b013e3283496502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 763 |
Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Mellado P, Monteagudo I, Llorca J, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother. 2012;67:170-173. [PMID: 21965436 DOI: 10.1093/jac/dkr410] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 764 |
Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am 2011;95:761-91, viii. [PMID: 21679791 DOI: 10.1016/j.mcna.2011.03.012] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 765 |
Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17(35): 3971-3975 [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 117] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 766 |
Asadi-Pooya AA, Dehghani SM, Petramfar P, Emami M, Mahmoodi M. Helicobacter pylori infection in patients with epilepsy. Seizure. 2012;21:21-23. [PMID: 21903421 DOI: 10.1016/j.seizure.2011.08.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 767 |
Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011;34:604-17. [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 121] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 768 |
Lee JW, Kim N, Nam RH, Park JH, Kim JM, Jung HC, Song IS. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea. Helicobacter 2011;16:301-10. [PMID: 21762270 DOI: 10.1111/j.1523-5378.2011.00840.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 769 |
Chung JW, Lee JH, Jung HY, Yun SC, Oh TH, Choi KD, Song HJ, Lee GH, Kim JH. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011;16:289-94. [PMID: 21762268 DOI: 10.1111/j.1523-5378.2011.00844.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 770 |
Redéen S, Petersson F, Törnkrantz E, Levander H, Mårdh E, Borch K. Reliability of Diagnostic Tests for Helicobacter pylori Infection. Gastroenterol Res Pract 2011;2011:940650. [PMID: 21826138 DOI: 10.1155/2011/940650] [Cited by in Crossref: 41] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 771 |
Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378:507-514. [PMID: 21777974 DOI: 10.1016/s0140-6736(11)60825-8] [Cited by in Crossref: 177] [Cited by in F6Publishing: 209] [Article Influence: 14.8] [Reference Citation Analysis]
|
| 772 |
Hung IF, Wong BC. Assessing the risks and benefits of treating Helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:141-147. [PMID: 21180540 DOI: 10.1177/1756283x08100279] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 773 |
O'Connor JP, Taneike I, O'Morain C. Improving compliance with helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;2:273-279. [PMID: 21180555 DOI: 10.1177/1756283x09337342] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 774 |
Miendje Deyi VY, Burette A, Bentatou Z, Maaroufi Y, Bontems P, Lepage P, Reynders M. Practical use of GenoType® HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing. Diagn Microbiol Infect Dis. 2011;70:557-560. [PMID: 21696906 DOI: 10.1016/j.diagmicrobio.2011.05.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 775 |
Wilhelm SM, Johnson JL, Kale-pradhan PB. Treating Bugs with Bugs: The Role of Probiotics as Adjunctive Therapy for Helicobacter pylori. Ann Pharmacother 2011;45:960-6. [DOI: 10.1345/aph.1q104] [Cited by in Crossref: 38] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 776 |
Luther J, Chey WD, Saad RJ. A clinician’s guide to salvage therapy for persistent Helicobacter pylori infection. Hosp Pract (1995). 2011;39:133-140. [PMID: 21441768 DOI: 10.3810/hp.2011.02.383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 777 |
Choi J, Kim CH, Kim D, Chung SJ, Song JH, Kang JM, Yang JI, Park MJ, Kim YS, Yim JY, Lim SH, Kim JS, Jung HC, Song IS. Prospective evaluation of a new stool antigen test for the detection of Helicobacter pylori, in comparison with histology, rapid urease test, (13)C-urea breath test, and serology. J Gastroenterol Hepatol 2011;26:1053-9. [PMID: 21362044 DOI: 10.1111/j.1440-1746.2011.06705.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 778 |
Schmilovitz-Weiss H, Shalev T, Chechoulin Y, Levi Z, Yishai R, Sehayek-Shabbat V, Niv Y, Shirin H. High eradication rates of Helicobacter pylori infection following sequential therapy: the Israeli experience treating naïve patients. Helicobacter 2011;16:229-33. [PMID: 21585609 DOI: 10.1111/j.1523-5378.2011.00834.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 779 |
Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2011;66:1847-1852. [PMID: 21632579 DOI: 10.1093/jac/dkr217] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 780 |
Wu C, Chen X |
